

SUBJECT INDEX

- A**
- Acetaminophen, 181–88
 - bioactivation of, 183
 - hepatic enzymes inhibited by, 186
 - hepatotoxicity and, 179–80
 - Acetamidiprid, 247–61 *passim*
 - 2-Acetylaminofluorene (AAF), 33–34
 - Acute coronary syndromes
 - plaque and, 99
 - Addictive drugs
 - adenosine and, 399–400
 - Adenosine, 385–404
 - addictive drugs and, 399–400
 - anxiety and, 401–2
 - caffeine and, 392–93
 - ischemia and, 391–92, 404
 - knockout mice, 385–404
 - multiple sclerosis and, 400
 - pain and, 403
 - receptors
 - aggression and, 402
 - central nervous system (CNS) and, 385–404
 - depression and, 402
 - Huntington's disease and, 398
 - locomotion and, 395–96
 - memory and, 400–1
 - morphine dependence and, 399–400
 - Parkinson's disease and, 396–98
 - schizophrenia and, 398
 - seizures and, 400
 - sleep and, 393–95
 - Adipocyte(s), 618–19
 - adiponectin and, 128–29
 - brown, 136
 - differentiation, 135–36
 - functional role of, 120–21
 - insulin signaling in, 123–24
 - interleukin-6 (IL-6) and, 127–28
 - leptin and, 126–27
 - partitioning of fat and, 134–35
 - resistin and, 129–30
 - secretions, 126–32, 136
 - white
 - conversion into brown-like cells, 135–36
 - Adipokines, 120–21
 - Adiponectin
 - hepatic fibrosis and, 619
 - insulin sensitizing and, 128–29
 - obesity treatment and, 134, 135
 - Adipose tissue(s) (AT), 119
 - brown adipose tissue (BAT), 119–20
 - cytokines and, 130
 - development, 135–36
 - macrophages accumulate in, 130–31
 - white adipose tissue (WAT), 119–21
 - Adrenergic receptors (ARs)
 - lipolysis in adipose tissue and, 121–23
 - obesity treatment and, 133
 - Adverse drug event (ADE)
 - with health products (HPs), 203, 220
 - Adverse drug reactions (ADRs), 177
 - benzbromarone and, 481
 - CYP2C9 and, 477–78, 488
 - Aflatoxin, 181
 - Aggression
 - adenosine receptors and, 402
 - Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), 89–90, 100
 - Aldosterone antagonist
 - therapy, 669–70, 678
 - Allogeneic cell
 - transplantation
 - imatinib mesylate and, 365
 - Allosterism, 291–305
 - Alpha blockers
 - acetaminophen and, 188
 - α -Tocopherol
 - antifibrotic properties, 615
 - Alprazolam
 - garlic and, 213
 - St. John's wort and, 216
 - Alzheimer's disease (AD)
 - dual-specificity
 - phosphatases (DSPases) and, 725, 737, 738, 742
 - glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and, 279, 280, 282, 283
 - proteomic approaches to, 233
 - statins and, 104
 - See also
 - Neurodegeneration;
 - Neurodegenerative disease
 - Amines
 - reaction with nitroxyl (HNO), 341

- Amino acids
 M.J. Coon's work on, 2, 3
 CYP2C9 and, 481-83
 glutathione transferases (GSTs) and, 58
 human epoxide hydrolases (EHs) and, 313-17
- 1-Aminobenzotriazole (ABT), 423-24
- Amiodarone, 480-81
- Amithiazole
 tuberculosis (TB) and, 531
- Amodiaquine
 malaria and, 576
- Ampicillin
 health products (HPs) and, 213
- Amyloid plaque formation, 104
- Anesthetic(s)
 degradation products, 147-67
 toxicity, 188-89
- Angiogenesis
 anticancer therapy and, 374
 multiple myeloma (MM) pathogenesis and, 466
 statins and, 96
- Angiotensin-converting enzyme (ACE)
 inhibitors, 668, 669
- Angiotensin system
 hepatic fibrosis and, 616-17
- Anglo-Scandinavian Cardiac Outcome Trial
 Lipid-lowering Arm (ASCOT-LLA), 90, 107
- Animal(s)
 models
 hepatic fibrosis and, 611
 pest insect control on, 250, 261
 See also Mice; Mouse
- Antibiotics
 health products (HPs) and, 213
- nongrowing bacteria and, 532
- Anti-cytokine therapies, 671-72
- Antidepressant agents
 adenosine receptors and, 402
- Antimalarial drug resistance, 565-78
 strategies to combat, 575-77
- Antioxidant effects
 statins and, 96
- Antioxidant mechanisms
 of statins, 97
- Antioxidant response
 glutathione transferases (GSTs) and, 51, 73-75
- Antioxidants
 antifibrotic properties, 615
- Antisense oligonucleotides (ODNs)
 20-hydroxyeicosate-traenoic acid (20-HETE) and, 427-28
- Antituberculosis drugs
 history of, 530-32
- Anxiety
 adenosine and, 401-2
 aprepitant and, 238
 tests, 234
- Apolipoprotein E (APOE4), 104
- Apoptosis
 bortezomib-induced, 469
 cancer and, 465-67
 cannabinoids and, 619
 fibrogenic cells and, 609
 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and, 269-74, 280, 281, 283
 hepatic fibrogenic cells and, 617
 hepatocyte
 liver fibrogenesis and, 612
- inhibitors of apoptosis proteins (IAPs), 470
 proteasome inhibition and, 471
- Aprepitant, 237-38
- Arachidonic acid
 CYP2C9 and, 487
 metabolism of, 413-14
- Arachidonic acid
 ω -hydroxylases, 413-29
 inhibitors of, 424
 regulation of, 418-28
- Arbitrary primed PCR (AP-PCR), 641
- Arrhythmia
 cardiac fibrosis and, 665-66
- Arrhythmogenesis
 myocardial fibrosis and, 669
- Arrhythmogenic right ventricular dysplasia (ARVD), 666
- Artemether
 malaria and, 576
- Artemisinin
 malaria and, 575-77
- Arteriosclerosis, 97
- Artichoke
 tinctures of, 210
- Arylamine(s), 27-39
 bioactivation of, 28-30
 carcinogenic, 32
 heterocyclic arylamine (HAA) adducts and, 33
 mutagenicity and, 30
 toxicity of, 27
- Atherosclerosis
 C-reactive protein (hs-CRP) and, 100
 endothelial dysfunction and, 95
 inflammatory process, 99
 plasma cholesterol and, 89
 soluble epoxide hydrolases (sEHs) and, 324
- Atherosclerotic plaques

statins and, 99–100, 103
 Atorvastatin, 90, 91, 706–7
 multiple sclerosis and, 104
 Atovaquone
 malaria and, 574–77
 Atrial natriuretic peptide
 (ANP)
 fat mobilization and, 124
 Australia
 natural health products
 and, 204
 Avastin[®], 371, 374–75
 5-Azacytidine, 646
 Azole drugs, 540

B

Bacillus thuringiensis (Bt)
 δ -endotoxin, 247, 250
 Bacteria
 tuberculosis (TB) therapy
 and, 532–33
 Bacterial infections
 treatment of, 532–33
 Baptist, James, 5
 Barberry, 214–15
 Barium hydroxide lime
 generation of carbon
 monoxide and, 166–67
 BCG vaccine, 539, 551
 Benzbromarone
 inhibitor of CYP2C9, 481
 β -Amyloid precursor protein
 (β -APP)
 Alzheimer's disease and,
 279
 Bevacizumab, 371, 374–75
 Binding site
 neonicotinoids and, 259–61
 Bioactivation
 arylamines and
 heterocyclic arylamine
 (HAA) and, 28–30
 hepatocarcinogenesis and,
 181
 hepatotoxicity and, 177–97
 Biological networks, 587
 Biomarker(s)

integrating data, 228
 prospective collection, 239
 psychotropic drug
 development and, 227–41
 retrospective collection of,
 237–38
 Biotransformations
 neonicotinoids and,
 253–55
 Bisulfite
 DNA methylation and,
 630–32
 Blast crisis
 imatinib mesylate and,
 364–65

Blood pressure
 epoxide hydrolases (EHs)
 and, 311, 323–24

Bone marrow cells, 608
 Bone marrow stromal cells
 (BMSCs)
 multiple myeloma (MM)
 and, 466, 468, 469

Bortezomib, 515
 myeloma treatment with,
 465–73
 phase I trials of, 471–72
 phase II study, 472–73
 resistance, 470–71

Brain natriuretic peptide
 (BNP), 124

Breast cancer
 treatment of, 372–73, 375,
 376

Breast cancer resistance
 protein (BCRP), 697

Bromfenac, 192
 2-Bromo-2-chloro-1,1-
 difluoroethylene,
 152–53

Bromobenzene
 hepatotoxicity and, 181

C

C-8-methoxy-FQ
 moxifloxacin (MXF),
 538–39

C-reactive protein (hs-CRP)
 statins and, 100–1

Caffeine, 34, 388, 391
 adenosine and, 392–93,
 401
 hypnotic effect of ethanol
 and, 399

Calcitonin gene-related
 peptide (CGRP), 348

Calcitonin-receptor-like
 receptor (CRLR), 348

Calendula flower
 tinctures of, 210

cAMP
 and nitroxy (HNO), 348

Canada
 herbal products (HPs) and,
 204

Cancer(s)
 cell-cycle progression, 358
 cells

marker of, 643

chemotherapy
 glutathione transferases
 (GSTs) and, 55

DNA methylation and,
 629–48

dual-specificity
 phosphatases (DSPases)
 and, 725, 737, 742

epoxide hydrolases (EHs)
 and, 311

glutathione transferases
 (GSTs) and, 52, 55, 75

heterocyclic arylamine
 (HAA) and, 39

molecular cancer
 therapeutics, 357–77

mutation and, 30, 32–33
 patients

aprepitant and, 237–38
 risk

heterocyclic arylamine
 (HAA) and, 38

studies
 arylamines and, 33

therapy

- DNA methylation drugs
in, 645-47
- histone deacetylase
(HDAC) inhibitors for,
495-517
- proteasome for, 467-68
- treatment of
predictor of response to,
644-45
- proteasome inhibition
for, 465-73
- tyrosine kinase
inhibitors for, 357-77
- tyrosine kinases and,
375-76
- See also Carcinogenesis;
Carcinogenicity;
Carcinogens; Colorectal
carcinoma; Lung cancer;
Lymphoma
- Cannabis smoking
hepatic fibrosis and,
619-20
- Carbamazepine, 191, 218
- Carbon dioxide
panic provocation by, 239
- provocative anxiety tests
and, 234, 237
- Carbon monoxide
formation from anesthetic
agents, 148, 166-67
- toxicity, 167-69
- Carbon tetrachloride
hepatotoxicity and, 181
- Carcinogenesis
DNA hypomethylation
and, 636
- mutagenesis and, 32
- See also Cancer(s)
- Carcinogenicity
heterocyclic arylamine
(HAA) and, 36
- See also Cancer(s)
- Carcinogens
glutathione transferases
(GSTs) and, 51, 52, 54
- P450 enzymes and, 34
- See also Cancer(s)
- Cardiac fibroblast(s), 657-79
- biology of, 658-63
- myocardium and, 658-61
- responses to exercise
training, 677
- therapies directed at,
666-74
- unanswered questions
about, 674-77
- unique cell type, 662-63
- Cardiac fibrosis, 663-66
- ACE inhibitors and, 668
- arrhythmia and, 665-66
- chronic injury and, 675
- heart disease and, 678-79
- targeting, 669-70
- Cardiac function
statins and, 102
- Cardiac hypertrophy, 101
- Cardiomyopathies
dilated and ischemic,
664-65
- Cardiomyopathy
statins and, 102
- Cardiovascular disease
CYP2C9 and, 487
- Cardiovascular exercise
training
adverse cardiac events and,
676-77
- Catalytic components
epoxide hydrolases (EHs)
and, 313-15
- Catalytic cycle
epoxide hydrolases (EHs)
and, 315-17
- Caveolae
cell signaling, 591-98
- Caveolin-GFP (green
fluorescent protein)
caveolae and, 591-92
- Cdc25, 732-34, 737-38,
740-42
- cell cycle and, 731-32,
735, 737-38
- dual-specificity
phosphatases (DSPases),
727-33, 737-38
- phosphatases, 726-27
- regulation, 730-31
- Cell culture models
hepatic fibrosis and,
610-11
- Cell cycle
Cdc25 and, 731-32, 735,
737-38
- Cell fractionation
cell signaling and, 588,
592-93
- Cell signaling
caveolae, 591-98
- compartmentalization of
signaling units and, 588
- compartments of, 591-98
- networks, 587-98
- organization of a signaling
unit, 588-91
- signal transduction and,
596-98
- units
in a compartment,
593-96
- Cell wall synthesis
inhibitors of, 534, 536-37
- tuberculosis (TB) and,
546-47
- Cellular polyubiquitination
machinery, 440-42
- Central nervous system
(CNS)
drug access to, 230-31
- proteome database, 233
- Cephalosporin antibiotics,
710
- Cerivastatin, 90, 91, 102,
705-8
- Cetuximab (C-225), 371, 374
- CGP57148
See Imatinib mesylate
- CGP 3466, 280
- Chamomile
drug metabolizing enzymes
and, 215

- Chemokines
 hepatic fibrosis and, 608
 synthesis of, 609
- Chemotherapy, 465–66, 468
 glutathione transferases (GSTs) and, 55
 tuberculosis (TB), 529–51
- Chinese medicine, 217–19
- Chloroquine
 malaria and, 565–71, 573, 577
- Chlorpromazine (CPZ), 541
- Cholecystokinin (CCK)
 panic provocation by, 239
 provocative anxiety tests and, 234, 237
- Cholesterol
 statins and, 91, 95, 106–8
- Cholesterol
 biosynthesis in the liver, 90
 caveolae and, 597
 ischemic stroke and, 102–3
 statins and, 89–91, 95, 98, 99, 102, 104–8
- Cholesterol epoxide
 hydrolase (chEH), 317–18
- Cholesterol and Recurrent Events (CARE), 89, 100, 107
- Chronic eosinophilic leukemia
 imatinib mesylate and, 366
 See also Leukemia
- Chronic myelogenous leukemia (CML)
 imatinib mesylate and, 361–65, 370
 treatment of, 360–65
 See also Leukemia
- Chronic myelomonocytic leukemia (CML), 367
 See also Leukemia
- Cigarette smoke
 heterocyclic arylamines (HAAs) in, 28
- CIMMiner, 228
- Cirrhosis
 liver, 605, 619
 regression, 606
- Citrus
 CYP enzymes and, 211
- Clinical Informatics and Bioinformatics to Biomedical Informatics, 229
- Clinical trials
 with statins, 89–90, 105–8
- Clofazimine, 541
- Clothianidin, 247–61 *passim*
- Clotrimazole, 540
- Clove, 217
- Coartemether
 malaria and, 576
- Collagen
 cardiac ECM and, 658–59
 dilated and ischemic cardiomyopathies and, 664–65
 extracellular metabolism of, 659–61
- Colorectal carcinoma
 treatment of, 374–76
 See also Cancer(s)
- Compartment(s)
 cell
 migratory, 597
 cell signaling, 591–98
 cellular, 592–93
- Compartmentalization
 cell signaling and, 588, 590–91, 593, 596
 signaling networks and, 598
- Compound A
 sevoflurane and, 147–48, 157–66
 toxicity and, 162–66
- Computerized tomography (CT) scans
 gastrointestinal stromal tumors (GIST) and, 368
- Congestive heart failure
 statin(s) and, 102, 670
- See also Heart disease;
 Heart failure
- Coronary artery disease (CAD), 96
- C-reactive protein (hs-CRP) and, 100
- Coronary heart disease (CHD)
 statins and, 89–90, 105, 107
 See also Heart disease
- Cortisol
 lipolysis and, 125
 visceral adiposity and, 132
- CpGs
 island(s), 629–31, 634–48
 methyl-CpG, 629, 633–34, 641
- Cranberry juice
 warfarin and, 212
- Crops
 genetically modified, 247, 250
- CSF
 proteomics and, 233
 psychotropic drug development and, 240
- Cyanamide
 nitroxyl (HNO) and, 346–47
- Cycloserine (CS), 531, 535–37
- Cyclosporin
 St. John's wort and, 216
- Cyclosporin A, 705–7
- CYP arachidonic acid ω -hydroxylases, 415–18
 regulation of, 418–28
- CYP enzymes
 allosterism, 291–305
 atypical kinetics of, 291–305
 citrus and, 211
 Echinacea and, 208, 209
 furanocoumarins and, 211
 garlic and, 208, 212
 Ginkgo biloba and, 213

- goldenseal and, 213-15
 health products (HPs) and, 220
 herbal tinctures and, 210-11
 kava and, 215
 milk thistle and, 215-16
 multiple ligand binding, 291-92, 296, 300-3
 spices and, 217
 St. John's wort and, 217
 traditional medicine plants and, 217-19
 x-ray structure of, 302
 See also Cytochrome P450 (CYP 450)
- CYP ω -hydroxylases
 inhibition of, 422-29
- CYP3A
 immunoblotting analysis and, 454-57
 ubiquitination, 439, 446-47, 449-52
- CYP3A4, 705, 707, 708
 mutagenesis of, 484
 ubiquitination and, 447, 447n.3, 455
- CYP4A, 413, 414, 415-18
- CYP2C8, 705, 707, 708
- CYP2C9, 477-88
 atypical kinetics, 483-84
 endogenous metabolism and, 487-88
 ethnic-specific, 485-86
 gene regulation of, 486-87
 inhibitor-based models of, 480
 inhibitors, 480-82
 ligand-based models for, 480-81
 pharmacogenetics, 484-86
 polymorphisms, 478, 484-86
 structure, 481-83
 substrate probes for, 478-79
 substrates for, 478-79
- CYP2C11
 ubiquitination and, 439, 447-49
- CYP2E1
 inactivation, 445-46
 ubiquitination and, 448-49, 452-53
- CYP4F, 413, 414, 415-18
 inhibition of, 429
- Cytochrome P450 (CYP 450), 6-17, 189
 arachidonic acid and, 413-14
 arylamines and heterocyclic arylamines and, 27-39
 bioactivation by, 181
 cellular locus, 449
 detection of, 453-57
 herbal products and, 203-21
 imidacloprid (IMI) metabolism and, 255
 multiplicity of, 7-11
 non-Michaelis-Menten kinetics and, 291-305
 oxidants and, 15-17
 proteasomal degradation and, 451-52
 reactive metabolites and, 178
 tuberculosis (TB) drug development and, 540
 ubiquitination, 439-57
- Cytokine(s), 131
 adipose tissue and, 130
 cancer and, 466, 468
 fibrogenic inhibition of, 613-15
 hepatic fibrosis and, 608
 signaling, 640
 synthesis of, 609
- Cytosolic glutathione transferase(s) (GSTs), 51, 52, 58, 60-65
 genes disruption of, 68-73
- polymorphisms in, 51, 66-68
- Cytotoxicity
 2-bromo-2-chloro-1,1-difluoroethylene and, 156
 Compound A, 164-65
 dichloroacetylene and, 151
- D**
- Dandelion
 drug metabolizing enzymes and, 215
- Dapsone, 37, 38, 483, 484
- Data Integration for the Pharmaceutical Industry, 228
- De le ke chuan kang, 217
- Decitabine, 645-46
- Dementia
 statins and, 104-5
- Den, Halina, 5
- Dentatorubral-pallidolysian atrophy (DRPLA), 277
- Deoxymyoglobin
 reacts with nitroxyl (HNO), 345
- Depression
 adenosine receptors and, 402
 aprepitant and, 238
 statins and, 104, 105
- Deprotonation
 nitroxyl (HNO) and, 336-37, 339, 344
- Dermatofibrosarcoma protuberans, 367
- Desflurane
 carbon monoxide formation from, 148, 166-67
- Dexamethasone (Dex), 465, 472, 473
- dextromethorphan
 garlic and, 213
- Diabetes
 arachidonic acid

- ω -hydroxylation and, 413, 429
 CYP4A expression and, 422
 tumor necrosis factor- α (TNF- α) and, 130
 type 2, 120, 136
 drugs for, 194
 obesity and, 119
 Diazepam
 binding sites, 300
 Dichloroacetylene
 trichloroethylene and, 147–52
 Diclofenac
 CYP2C9 and, 478–79, 481, 482
 hepatotoxicity and, 192–94
 metabolic bioactivation of, 194
 Dietary Supplements Health and Education Act (DSHEA), 204
 Differential methylation
 hybridization (DMH), 642
 Digoxin, 708–9
 Dihydralazine, 37, 38
 Dihydroartemisinin
 malaria and, 576
 Dihydrofolate reductase
 antimalarial drug resistance and, 573, 575
 malaria parasites and, 572
 Dihydropteroate synthase
 antimalarial drug resistance and, 573, 575
 Dilated and ischemic cardiomyopathies (DCM), 664–65
 Diltiazem
 Ginkgo biloba and, 213
 Dimerization
 nitroxyl (HNO), 337, 343, 344
 Dinotefuran, 247–61 *passim*
 Dioxygen
 reaction with nitroxyl (HNO), 341–42, 347–48
 Diseased states
 aberrant DSPase regulation in, 737–42
 Dithiothreitol
 for acetaminophen intoxication, 184
 DNA
 damage
 nitroxyl (HNO) and, 347
 repair, 639–40
 DNA adduct(s), 35, 36, 181
 arylamines and
 heterocyclic arylamines (HAAs) and, 30–33
 biomarkers of, 32
 DNA methylation
 cancer and, 629–48
 CpG islands and, 635
 establishment and signaling, 632–34
 DNA methyltransferases (DNMTs), 631–33, 636, 637
 Donepezil, 279
 Dopamine
 striatum and, 395–98
 Dose-limiting toxicities (DLTs)
 bortezomib and, 471, 472
 Doxycycline, 678
 malaria and, 576
 Drug(s)
 adenosine receptor effects and, 404
 antimalarial, 565–78
 bioactivation
 hepatotoxicity and, 188–95
 clearance, 293
 design
 structure-based, 548–49
 designer
 cancer therapy and, 376
 development process, 227
 discovery
 integromics and, 228
 discovery efforts, 739–42
 disposition
 health products and, 203–21
 drug-drug interaction(s)
 CYP2C9 and, 478, 480, 481
 transporters and, 689–711
 drug-receptor interactions
 measuring, 231–33
 drug-resistant tuberculosis, 529–30
 herb-drug interactions, 206
 liver and kidney transport of, 689–711
 new tuberculosis (TB)
 targets of, 542–48
 obesity treatment and, 133–34
 psychotropic, 228–30
 resistance
 antimalarial, 565–78
 screens
 tuberculosis (TB), 549–51
 toxicity, 37
 tuberculosis (TB), 533–38
 See also Drug metabolism
 Drug metabolism
 CYP2C9 and, 478, 484, 487, 488
 CYPs and, 291, 294–95, 304
 hepatotoxicity and, 178–80
 P450 enzymes and, 9–12
 symposia and conferences on, 6–8
 See also Drug(s)
 Dual-specificity mitogen-activated protein kinase phosphatases (DS-MKPs), 733–37
 neoplastic disease and, 738–39

- regulation, 736–37
- Dual-specificity phosphatases (DSPases), 725–42
- therapeutic targets, 739–42
- Duloxetine, 234–36
- Dynabridge study, 231
- E**
- Echinacea
- ampicillin and, 213
- Echinacea*, 210
- CYP enzymes and, 208, 209
- labeling information, 207–8
- Eicosanoids
- glutathione transferases (GSTs) and, 58–59, 65
- Endogenous metabolism
- CYP2C9 and, 487–88
- Endoplasmic reticulum (ER)-associated degradation (ERAD), 447n.3, 449–52
- Endothelial-derived
- hyperpolarization factor (EDHF)
- CYP2C9 and, 487
- Endothelial NO synthase (eNOS)
- cell signaling and, 594–96
- statins and, 95–96, 98, 100, 103
- Endothelial progenitor cells (EPCs)
- statins and, 96–98, 103
- Endothelin-1
- hepatic fibrosis and, 616
- Endothelin receptor
- antagonists
- heart failure and, 670
- Endothelium
- statins and, 95–96
- Enflurane, 189
- carbon monoxide
- formation from, 148, 166–67
- eNOS
- See Endothelial NO synthase (eNOS)
- Epidermal growth factor receptor (EGFR)
- cancer therapy and, 358, 373–76
- inhibitors
- lung cancer and, 376
- receptor tyrosine kinase, 371–72, 375–76
- solid tumors and, 359
- Epigenetic changes
- cancer and, 630, 647
- Epigenetic modification
- humans and, 634–35
- Eplerenone, 669
- Epoxide hydrolases (EHs), 311–24
- catalytic components, 313–15
- catalytic cycle, 315–17
- cholesterol epoxide hydrolases (chEH), 317–18
- inhibitor designs, 319–21
- mechanism, 312–19
- microsomal
- inhibitors, 319–21
- microsomal epoxide hydrolases (mEHs), 312–17, 321–24
- structure, 319
- soluble epoxide hydrolases (sEHs), 312–17, 321–24
- inhibitors, 319–21
- structures, 318–19
- Epoxides
- glutathione transferases (GSTs) and, 54
- Epoxyeicosatrienoic acids (EETs), 414
- CYP2C9 and, 487–88
- vasodilatory properties of, 323–24
- EPXH2 gene, 318–19
- Erbix[®], 371, 374
- ERK 1/2 protein kinases
- cell signaling and, 589–91, 594
- Erlotinib, 373–74
- Ethambutol (EMB), 531–36, 546, 549
- Ethanol
- hypnotic effect of, 399
- Ethionamide (ETH), 531, 534, 535, 546
- Ethnic populations
- CYP2C9 polymorphisms and, 485–86
- Europe
- herbal products (HPs) and, 204
- European Scientific Cooperative on Phytotherapy (ESCoP), 204
- EXPH2 gene
- structure, 319
- Extracellular matrix (ECM), 664
- cardiac fibroblasts and, 658–59, 661
- deposition, 663, 665
- metabolism, 661, 662, 668–70, 675, 678
- inhibitors of, 672–73
- remodeling, 661, 672, 676–78
- F**
- Fansidar[®], 572
- Farnesylpyrophosphate (FPP)
- statins and, 92, 95, 98
- Fat
- cells, 119–37
- distribution, 121
- partitioning of, 134–35
- Feverfew tea, 210
- Fexofenadine
- St. John's wort and, 216–17
- Fibrogenesis
- hepatic, 610

- Fibrogenic cells
liver, 606–8
proliferation and increased survival, 609
- Flavonoid sylimarin
antifibrotic properties, 615
- Fluorescence resonance energy transfer (FRET)
probes
cell signaling and, 595–96
- Fluoroquinolones (FQ), 533, 534, 537–39
malaria and, 576
- Fluoxetine
retrospective biomarker collection and, 237–38
- Flurbiprofen
CYP2C9 and, 479, 483, 484
- Fluvastatin, 90, 91
- Folate biosynthesis
malaria parasites and, 572
- Folic acid antagonists
malaria and, 571–74
- Fosmidomycin
malaria and, 577
- Framingham Heart Study, 90, 102
- Furanocoumarins
CYP enzymes and, 211
- Furosemide
hepatotoxicity and, 181
- G**
- Garlic, 208, 212–13
- Gastrointestinal stromal tumors (GIST), 359, 367–69
imatinib mesylate and, 360, 376
- Gefitinib, 371, 373, 739
- Ge-gen, 218
- Gemfibrozil, 707–8
- Gene(s)
activated by DNA
hypermethylation, 637–40
CpG islands and, 630
- CYP2C9, 477–88
expression systems
drug-drug interactions and, 699
hypermethylated
finding, 641–42
silencing
tumor suppressor genes and, 634–40, 646–48
targeting
tuberculosis (TB) and, 544
- Genomics, 228
- Geranylgeranylpyrophosphate (GGPP)
statins and, 92, 95, 98
- Ginger, 217
- Ginkgo biloba*
diltiazem and, 213
- Gleevec[®], 514, 515, 739
See also Imatinib mesylate
- Glitazones, 195
metabolism and toxicity of, 196
- Glivec[®]
See Imatinib mesylate
- Glutathione (GSH)
glutathione transferases (GSTs) and, 52, 54–58
metabolism
antimalarial drugs and, 577
reaction with nitroxyl (HNO), 343
- Glutathione transferases (GSTs), 51–76
amino acids and, 58
bioactivation by, 181
bioactivation of
xenobiotics by, 55
cytosolic, 51, 52, 58, 60–65
eicosanoids and, 58–59, 65
fold, 63–65
genes
knockout of, 68–73
genetic variation in, 51, 66–68
- Keap1/Nrf2 pathway and, 73–76
metabolism of endogenous compounds by, 55–60, 76
metabolism of xenobiotics by, 54–55
mitochondrial, 51, 52, 62
modulation of signaling pathways by, 59–60
tumorigenesis and, 75
- Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 269–83
Alzheimer's disease and, 279, 280, 282, 283
apoptosis and, 269–74, 280, 281, 283
ischemia stroke and, 281
neurodegenerative diseases and, 269, 276–83
nuclear accumulation, 269, 271–72, 280, 281, 283
nuclear translocation, 269, 272–74, 280, 282, 283
overexpression, 270–72, 280, 281, 283
oxidative stress, 269, 274–76, 281
Parkinson's disease (PD) and, 280, 282
stroke and, 280–81
- Goldenseal, 210
CYP enzymes and, 213–15
- Goldenthread, 214–15
- GoMiner, 228
- Growth hormone (GH)
lipid mobilization and, 124
obesity treatment and, 133
- Guanosine triphosphate (GTP)-binding proteins
cardiac hypertrophy and, 101
statins and, 92–95, 98
Gustavson, Reuben, 1–2

- H**
- Hair dyes, 28
- Haldane equation, 167-68
- Halothane
 bioactivation of, 190
 2-bromo-2-chloro-1,1-difluoroethylene and, 152-53
 immunoallergic hepatitis and, 188-91
- Health products (HPs)
 confounding factors in evaluations of, 208, 210, 220
 contaminated, 204-5
 drug disposition and, 203-21
 future clinical studies of, 220
 labeling information, 207-8
 product selection for clinical studies of, 219
 stability, 210-11
 variation, 205, 207
- Heart disease
 cardiac fibrosis and, 678-79
 hypertensive
 ACE inhibitors and, 668
 pandemic of, 657
 See also Congestive heart failure; Coronary heart disease (CHD); Heart failure
- Heart failure, 657-58, 661, 663, 675
 endothelin receptor antagonists and, 670
 hypertensive, 665
 nitroxyl (HNO) in the treatment of, 348, 349
 statins and, 102
 statins potential utility in, 670
 therapy
 ACE inhibitors and, 668
- See also Congestive heart failure; Heart disease
- Heart Protection Study (HPS), 90, 102, 104, 107
- Heart therapy
 cardiac fibroblasts in, 657-79
- Heme
 malaria parasites and, 568-69
- Hepatic enzymes
 inhibited by acetaminophen, 186
- Hepatic fibrosis, 605-20
 antifibrotic drugs and, 613-20
 antifibrotic strategies, 612-13
 matrix-producing cells and, 608-10
 models and assessment of, 610-11
 potential antifibrotic compounds and, 614
 progression and regression of, 606
 staging in humans, 611
- Hepatic microsomal system cytochrome P450 and, 6
- Hepatic myofibroblasts, 607-8, 610, 612, 615
 antifibrotic drugs and, 613-20
- Hepatic P450 ubiquitination, 439-57
- Hepatic stellate cells (HSC)
 cell culture models and, 610-11
 hepatic fibrosis and, 607-10, 612, 615, 619
- Hepatitis
 drug-induced, 37
 halothane and, 188-91
 halothane-associated, 152-53
 hepatitis B, 605, 606
 hepatitis C, 605, 606, 612, 615, 618, 619
 immune-mediated, 193
 isoniazid and, 192
- Hepatobiliary excretion
 of drugs, 690-91
 mechanism of, 691-92
- Hepatobiliary transport
 of drugs, 689-711
- Hepatocarcinogenesis
 bioactivation and, 181
- Hepatocyte growth factor (HGF), 615
- Hepatocytes
 to study drug uptake, 698
- Hepatotoxicity
 dichloroacetylene and, 151
 diclofenac and, 192-94
 drug bioactivation and, 188-95
 drug metabolism and, 178-80
 halothane-associated, 147
- Hepatotoxins
 bioactivation and, 181-88
- Herbal products (HPs), 203-21
- Herbal teas
 drug metabolizing enzymes and, 215
 evaluation of, 210
- Herbs
 herb-drug interactions, 206
 See also Herbal products (HPs)
- Herceptin®
 breast cancer and, 371-73
- 20-HETE, 413-29
- Heterocyclic arylamine(s) (HAAs), 27-39
 bioactivation of, 28-30
 cancer and, 39
 cancer risk and, 38
 carcinogenicity of, 33
 DNA adducts, 30, 33, 39
 genotoxicity, 32
 interspecies metabolism

- of, 35
 - mutagenicity, 30, 32–33
 - Heterotropic effects
 - allosteric kinetics and, 293–94, 299
 - Heterozygotes (HZ) mice
 - adenosine receptors and, 388–89
 - High performance capillary electrophoresis (HPCE), 631, 632, 647
 - Histone acetyltransferases (HATs), 495, 497, 503–4, 631
 - Histone code
 - transcriptional regulation and, 496–98
 - Histone deacetylase (HDAC) inhibitors
 - as anticancer agents, 495–517
 - Histone deacetylase(s) (HDACs), 631, 637, 646
 - classification of, 498, 500
 - inhibitors
 - antitumor activity, 510–17
 - antitumor mechanisms of, 503–9
 - clinical toxicity, 512–13
 - in combination with other agents, 513–17
 - pharmacokinetics and, 513, 517
 - structural classes and mechanistic actions of, 500–3
 - in vivo biological and clinical characteristics, 510–13
 - Histone methyltransferases (HMTs), 631
 - HIV infection
 - tuberculosis (TB) and, 529–30
 - HMG-CoA reductase
 - inhibitors, 89–108, 705–8
 - Homotropic effects
 - allosteric kinetics and, 293–94, 299
 - Honeybees
 - neonicotinoids harmful to, 251
 - Hormonal response, 640
 - Human genome studies
 - obesity and, 136–37
 - Humans
 - staging hepatic fibrosis in, 611
 - Huntington's disease (HD), 277–78, 280, 282, 283
 - adenosine receptors and, 398
 - 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase
 - inhibitors, 89–108, 705–8
 - 20-Hydroxyeicosatetraenoic acid (20-HETE), 413–29
 - antagonists, 428
 - biological significance of, 415
 - synthesis, 418–28
 - Hydroxyl alkyl-enzyme intermediate
 - formation of a, 312–13
 - Hydroxynaphthoquinones, 574
 - Hypercholesterolemia, 98
 - cardiac hypertrophy and, 101
 - Hyperemia
 - Compound A and, 163
 - Hypereosinophilic syndrome, 357
 - imatinib mesylate and, 366–67, 375
 - Hyperleptinemia, 134, 135
 - Hypertension
 - adverse effects on the heart, 665
 - arachidonic acid
 - ω -hydroxylation and, 413, 419–20, 429
 - soluble epoxide hydrolases (sEHs) and, 319, 324
 - Hypertensive heart disease
 - ACE inhibitors and, 668
 - Hypertrophic
 - cardiomyopathy (HCM), 664
 - Hypertrophy
 - cardiac, 101
 - Hypomethylation
 - cancer cell, 636
 - Hypoxia, 281, 391–92
- ## I
- Ibuprofen
 - CYP2C9 and, 482
 - IFN γ
 - idiopathic pulmonary fibrosis and, 671
 - Imaging studies
 - psychotropic drug development and, 240
 - Imaging techniques
 - measuring drug concentrations in brain tissue, 231
 - Imatinib mesylate, 366–67, 514, 515, 739
 - adverse effects of, 370
 - allogeneic cell transplantation and, 365
 - chronic myelogenous leukemia (CML) and, 361–65, 370
 - clinical use, 371
 - hypereosinophilic syndrome and, 366–67
 - pharmacology and, 370
 - prototype, 359–60
 - resistance to, 365–66
 - tumors and, 361–62, 375
 - Imidacloprid (IMI), 247–61
 - passim
 - Imidazoles
 - malaria and, 576
 - Immunoblotting analysis, 454
 - liver microsomes

- and, 454–57
- Immunocytochemistry
cell signaling and, 588, 594
- Immunofluorescence
cell signaling and, 593
- Immunogold probes
cell signaling and, 593
- Indinavir
goldenale and, 214
milk thistle and, 216
St. John's wort and, 216
- Infectious diseases
reemerging, 566
- Inflammation
arachidonic acid
 ω -hydroxylation and, 413, 429
CYP4A enzymes and, 421
CYP4F and, 416, 421–22
epoxide hydrolases (EHs)
and, 311, 319, 320, 324
vascular
statins and, 99–101, 108
- Insecticides, 247–61
glutathione transferases (GSTs) and, 52
history, 247–48
- Insects
neonicotinoids and, 247–61
- Institute for Genomic Research (TIGR), 548
- Insulin
adiponectin and, 128–29
sensitivity of fat cells, 131
signaling in adipocytes, 123–24
See also Insulin resistance
- Insulin resistance, 119, 134
adipokines and, 121
adiponectin and, 128
corticosteroids and, 125
nonesterified fatty acids (NEFAs) and, 120
resistin and, 129
tumor necrosis factor- α (TNF- α) and, 130
- Integromics
in drug discovery, 228
- Interferons
hepatic fibrosis and, 615
- Interleukin-6 (IL-6), 466, 468
adipocytes and, 127–28
- Interleukins
adipose tissue and, 130, 131
- Iressa[®], 371, 373, 739
- Ischemia
adenosine and, 391–92, 404
reperfusion
nitroxyl (HNO) and, 347
stroke, 281
- Isocitrate lyase (ICL), 544
- Isoflurane, 189
carbon monoxide
formation from, 148, 166–67
- Isoniazid (INH), 530–36, 539, 546, 550, 551
adverse reactions to, 192
metabolic bioactivation of, 193
- Isoprenoid
statins and, 89, 97, 108
- Isoprenylated proteins
statins and, 92–95, 108
- Isoprenylation
statins and, 92–95
- J**
- Japan
herbal products (HPs) and, 204
- K**
- Kanamycin, 531, 535
- Kava
CYP enzymes and, 215
- Keap1/Nrf2 pathway
glutathione transferases (GSTs) and, 73–76
- Kidney
damage
Compound A and, 165
- failure
soluble epoxide
hydrolases (sEHs) and, 324
mechanism of drug
elimination in, 690–91
slices
evaluating
drug/compound uptake
with, 697–98
transporters in, 693–95
- Kinetic(s)
allosteric, 293–96
atypical
of CYPs, 291–305
models
CYP, 296–300
- KIT**
cancer therapy and, 357, 358, 375, 376
gastrointestinal stromal tumors (GIST) and, 359, 367–69
mast cell disease and, 370
mutations
imatinib mesylate and, 360
solid tumors and, 376
- Krebs, Hans, 4
- Kupffer cells, 187, 191
- Kusunose, Masamichi, 5
- L**
- Lactacystin, 467
- Lactate
provocative anxiety tests
and, 234, 237
- Lamivudine, 606
- Left ventricular hypertrophy (LVH), 663, 665
- Leptin, 131, 134–35
adipocytes and, 126–27
- Leukemia
bortezomib and, 471
treatment of, 357, 360–67
- Leukotrienes (LTs)
glutathione transferases

- (GSTs) and, 51, 52, 59, 65-66
- Ligand(s)
- binding
 - CYPs and, 291-92, 296, 300-3
 - CYPs and, 295-97
- Linezolid, 540
- Lipid(s)
- caveolae and, 597
 - lipid-mobilizing factor (LMF), 125
 - mobilization, 124, 125
 - statins and, 99
- Lipid Research
- Clinic-Coronary Primary Prevention Trial (LRC-CPPT), 105
- Lipolysis
- adrenergic regulation of, 121-23
 - corticosteroids and, 125
 - cortisol and, 125
 - growth hormone and, 124
 - insulin and, 123
 - lipolytic peptides and, 124-25
 - miscellaneous agents of, 125-26
 - tumor necrosis factor- α (TNF- α) and, 125
- Lipopoptosis, 120
- Lipotoxicity, 120
- Lisinopril, 668
- Liver
- cholesterol biosynthesis in, 90
 - CYP2C9 and, 477, 478, 486
 - drug-drug interactions in, 702-3
 - fibrogenic cells of, 606-8
 - fibrosis, 605-20
 - inflammation
 - reduction of, 612
 - injury
 - drug-induced, 177-97
 - mechanism of drug elimination in, 691-92
 - myofibroblasts
 - cell culture models and, 610-11
 - slices
 - study of drug uptake with, 698
 - statins and, 92, 108
 - systems, 5-6
 - toxicity
 - drug-induced, 177-97
 - transporters, 695-97
- Locomotion
- adenosine receptors and, 395-96
- Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), 89
- Losartan, 668-69
- Lovastatin, 90-92
- Low-density lipoprotein (LDL)-containing cholesterol (LDL-C)
- statins and, 91, 95, 106-8
- Lu, Anthony, 6
- Lumefantrine
- malaria and, 576
- Lung cancer
- bortezomib and, 472
 - treatment of, 357, 373-76
 - See also Cancer(s)
- Lung congestion
- Compound A and, 163
- LY354740, 38, 239
- Lymphoma
- bortezomib and, 471
 - See also Cancer(s)
- ## M
- Macrophages
- accumulate in adipose tissue, 130-31
 - atherosclerotic plaques and, 99
- Maillard reaction
- heterocyclic arylamine (HAA) and, 28
- Malaria, 572-76
- antimalarial drug resistance and, 565-78
- Malarone[®], 575
- Malignancies
- tyrosine kinases and, 359
- Malignant melanoma
- bortezomib and, 472
- Mammals
- neonicotinoids and, 247-61
- Mast cell disease, 357, 369-70
- MatchMiner, 228
- Matrix metalloproteinase(s) (MMP), 659-60
- extracellular metabolism and, 672-73
 - hepatic stellate cells and, 610
 - inhibitors, 672, 677-78
 - MMP-1, 617
- Matrix-producing cells
- hepatic fibrosis and, 608-10
- Maximum tolerated dose (MTD)
- bortezomib and, 471, 472
- MedMiner, 228
- Mefloquine, 568, 575
- MEK
- cell signaling and, 589-90
- MEK1
- cell signaling and, 590, 594
- MEK2
- cell signaling and, 590
- Membrane-associated
- proteins in eicosanoid and glutathione (MAPEG), 51-52, 62, 65-66, 76
 - genes, 72-73
 - polymorphisms and, 68
- Membrane vesicles
- transport studies with, 698-99
- Memory

- adenosine receptors and, 400-1
- Metabolic activation
 - drug-induced
 - hepatotoxicity and, 177-97
- Metabolic syndrome, 119, 136
- leptin production and, 134-35
- nonesterified fatty acids (NEFAs) and, 120
- topography of fat distribution, 121
- Metabolites
 - hepatotoxicity and, 177-97
- Metalloproteins
 - nitroxyl (HNO) and, 345
 - See also Matrix metalloproteinase(s) (MMP)
- Methotrexate (MTX), 710-11
- Methoxyflurane, 147
- Methylation
 - DNA, 629-48
- Methylation-specific oligonucleotide (MSO) microarray, 642
- Methyl-CpG, 629, 633-34, 641
- Mevastatin, 90, 91
- Mevinolin, 90
- Mice
 - knockout
 - adenosine and, 385-404
 - See also Mouse
- Michaelis-Menten model
 - drug clearance and, 293
- Miconazole, 540
- Micro array tools
 - biomarker data and, 228
- Microscopy
 - light and electron
 - cell signaling and, 593
- Midazolam
 - binding sites, 300
- Milk thistle
 - CYP enzymes and, 215-16
 - tinctures of, 210
- Mitchison hypothesis, 533
- Mitochondrial glutathione transferases (GSTs), 51, 52, 62
- Mitogen-activated protein kinases (MAPKs), 726, 728, 732-35
- Mitogen-activated protein kinase kinases (MAPKKs), 589, 728
- Mitogen-activated protein kinase kinase kinases (MAPKKKs), 589, 728
- Mitogen-activated protein kinase phosphatases (MKPs), 726-27, 732-37, 742
- Molecular cancer
 - therapeutics, 357-77
- Molecular ecology, 597
- Molecular genetics
 - individual malignancies and, 358
- Molecular interactions
 - biological networks and, 587
- Molecular targets
 - antimalarial drugs and, 577
- Morphine dependence
 - adenosine receptors and, 399-400
- Mouse
 - glutathione transferase (GST) genes, 68-73
 - See also Mice
- Multicatalytic protease complex, 442-43
- Multidrug resistance (MDR)
 - associated proteins, 696-97
 - drug-drug interactions and, 704-5
 - transport, 708-9
 - transporter, 694, 697
- Multidrug
 - resistance-associated protein (MRP)
 - glutathione transferases (GSTs) and, 54
- Multidrug-resistant TB (MDR-TB), 530, 532, 537, 542, 546
- Multiple myeloma (MM), 465-73
 - pathogenesis, 466
 - phase II bortezomib studies in, 472-73
 - proteasome inhibitors (PIs) and, 465-73
- Multiple Risk Factor Intervention Trial (MRFIT), 90, 102
- Multiple sclerosis
 - adenosine and, 400
 - statins and, 104-5
- Mutagenesis
 - CYP2C9 and, 481-82
- Mutagenicity
 - 2-bromo-2-chloro-1,1-difluoroethylene and, 156-57
 - Compound A and, 165
 - dichloroacetylene and, 151
- Mutation(s)
 - antimalarial drug resistance and, 569-71, 573-75, 577
 - cancer and, 30, 32-33
- Mycobacterial persistence
 - targeting, 543-44
- Myeloma
 - bortezomib for treating, 465-73
- Myocardial fibrosis
 - arrhythmogenesis and, 669
- Myocardial infarction, 487
- Myocardium
 - cardiac fibroblasts and, 658-61
 - statins and, 101-2
- Myofibroblastic phenotype
 - acquisition of, 608-9

- N**
- N-acetyl-p-benzoquinoneimine (NAPQI)**, 183–85, 187
- N-acetylcysteine**
for acetaminophen intoxication, 184
- N-acetyltransferase (NAT)**, 30, 32
- Nasopharyngeal carcinoma**
bortezomib and, 472
See also Cancer(s)
- Natriuretic peptides**
obesity treatment and, 133
- Natural health products (NHPs)**
confounding factors in evaluations of, 210
- Natural Product Number**
for natural health products, 204
- Neonicotinoid(s)**, 247–61
biotransformations and, 253–55
nicotinic agonists and, 258–59
nicotinic receptors and, 255–58
toxicology, 250–53
- Neoplasms**
imatinib mesylate and, 375
malignant, 358
See also Cancer(s); Neoplastic disease
- Neoplastic disease**, 738–39
See also Neoplasms
- Nephrotoxicity**
2-bromo-2-chloro-1,1-difluoroethylene and, 156, 157
Compound A, 163–66
dichloroacetylene and, 149, 151, 152
sevoflurane and, 158
- Nerve neuropathies**
trichloroethylene and, 148, 152
- N-ethylmaleimide (NEM)**
P450 ubiquitination and, 453–55
- Network biology**, 587
- Neurodegeneration**
Cdc25 and, 737, 738
See also Alzheimer's disease (AD); Neurodegenerative disease
- Neurodegenerative disease**, 269, 276–83
See also Alzheimer's disease (AD); Neurodegeneration
- Neurohormonal imbalance**
statins and, 102
- Neuropathy**
fluoride-induced, 147
- Neurotoxicity**
dichloroacetylene and, 151
- Nevirapine**, 191
- Newburn, Mary Lou**, 3
- New York University**, 4
- NF- κ B**
bortezomib and, 471
cancer and, 468–69
proteasome inhibitors and, 468–70
- N-hydroxybenzene-sulfonamide**
nitroxyl (HNO) and, 343–44
- N-hydroxylamine**, 28
- N-hydroxylation**, 27, 33–37
- Nicotine**
toxicological profile, 251–52
- Nicotinic agonists**
neonicotinoids and, 258–59
- Nicotinic receptors**
neonicotinoids and, 255–58
- Nicotinoids**, 249–61 *passim*
- Nitenpyram**, 247–61 *passim*
- Nithiazine**, 247–61 *passim*
- Nitric oxide (NO)**
hepatic response to acetaminophen and, 188
lipolysis and, 125
nitroxyl (HNO) and, 335, 338, 339, 343, 344, 346
platelet aggregation and, 98
reaction with deoxyhemoglobin, 345
statins and, 95, 96, 100, 103
- Nitrofurantoin**, 540, 541
- Nitroimidazopyran (PA-824)**, 542
- Nitrosobenzene**, 345
- Nitrosyl hydride**, 336
- Nitroxide**, 336
- Nitroxyl (HNO)**, 335–49
biological generation of, 345–46
calcitonin gene-related peptide (CGRP) and, 348
as a cardiovascular agent, 348
chemical properties of, 336–39
cyanamide and, 346–47
deoxyhemoglobin reacts with, 345
deprotonation, 336–37, 339, 344
dimerization, 337, 343, 344
donors, 343–44, 348, 349
ischemia reperfusion and, 347
NMDA receptor and, 347–48
nomenclature, 336
pharmacology of, 346–49
pK_a of, 337–38
reaction with amines, 341
reaction with dioxygen, 341–42, 347–48
reaction with glutathione (GSH), 343
reactivity of, 339–43
tetracyanonickelate and, 344

- thiols, 340–41, 344, 346, 347
 toxicity of, 347
 traps and detectors for, 344–45
- NK-1 antagonists
 antidepressant research and, 237–38
- NMDA receptor
 nitroxyl (HNO) and, 347–48
- Nonesterified fatty acids (NEFAs), 120
 adipose tissue buffering of, 122
 growth hormone and, 124
 insulin and, 123, 124
 obesity treatment and, 133–34
- Non-Hodgkin's lymphoma (NHL)
 bortezomib and, 471
- Nonpeptide inhibitors, 467
- Nonsteroidal
 antiinflammatory drugs (NSAIDs), 192
 CYP2C9 and, 482, 483
 methotrexate (MTX) and, 710–11
- Norepinephrine (NE)
 drug studies and, 233–35
- Norepinephrine transporter (NET)
 drug studies and, 233–35
- NSAIDs
 See Nonsteroidal antiinflammatory drugs (NSAIDs)
- Nucleic acid synthesis
 inhibitors of, 537
- Nutraceuticals (NCs), 203–4
 labeling information, 207–8
 variation, 205, 207
- O**
- Obesity
 treatment of, 132–34, 136–37
 type 2 diabetes and, 119
- Ochoa, Severo, 4
- ONO-1603, 279
- Oregano, 217
- Oregon grape, 214–15
- Organic anion transporters (OATs)
 drug interactions and, 689, 703, 710
 renal, 694
- Organic anion transporting polypeptides (OATPs)
 drug-drug interactions and, 703–4
 drug interactions and, 689, 699, 700, 706–8
 liver, 695–96
- Organic cation transporters (OCT)
 kidney, 694–95
- Orlistat, 132
- Oxazolidinones, 540
- Oxidants
 cytochrome P450 and, 15–17
- Oxidations
 M.J. Coon's work on, 5
- Oxidative stress
 glutathione transferases (GSTs) and, 51, 52
 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and, 269, 274–76, 281
 hepatic fibrosis and, 615
 products
 detoxification of, 55–58
- Oxirane, 311–24
- Oxytocin receptors (OTR)
 caveolae and, 596–97
- P**
- p53
 tumor suppressor gene, 637
- P450
 See Cytochrome P450 (CYP 450)
- P. falciparum*, 565–66, 572, 574–77
 chloroquine-resistant, 569
- P. falciparum*
 chloroquine-resistance transporter (*pfcr*), 569–71, 575
- P. falciparum* multidrug resistance 1 (*pfmdr1*), 569–71
- P-glycoprotein (P-gp)
 inhibitor, 708
 kidney and liver, 694
- Pain
 adenosine and, 403
- Panic disorders
 adenosine and, 401–2
 provocative anxiety tests and, 234, 237
- Para-aminosalicylic acid (PAS), 531, 533–35
- Parenchymal injury, 608
 inhibition of, 612
- Parkinson's disease (PD)
 adenosine receptors and, 396–98
 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and, 280, 282
 proteomic approaches to, 233
- Passionflower
 tinctures of, 210
- PDGFR
 See Platelet-derived growth factor receptor (PDGFR)
- Peppermint
 drug metabolizing enzymes and, 215
- Peptide aldehydes, 467
- Peptide boronates, 467

- Peptide defomylase (PDF)
 inhibitors, 542
 Peptide hormones
 adipocytes and, 120
 Peptide transporters (PEPT)
 kidney, 694
 Peptides
 lipolysis and, 124–25
 vasoactive
 hepatic fibrosis and, 616
 Peptin
 hepatic fibrosis and, 18
 Peroxisome proliferator
 activated receptor
 gamma (PPAR γ)
 hepatic fibrosis and, 618
 Peroxisome
 proliferator-activated
 receptors (PPARs), 125,
 135
 cardioprotective, 674–77
 obesity treatment and, 134
 Pest insect control, 250, 261
 Pesticides
 See Insecticides
 Peterson, Bill, 5
 Pets
 pest insect control on, 250,
 261
 Pharmacogenetics and
 Pharmacogenomics
 Knowledge Base
 (PharmGKB), 229
 Pharmacotherapy
 unresolved issues for,
 677–79
 Phenacetin, 34
 Phenobarbital, 486
 Phenothiazines, 541
 Phenytoin, 478, 480, 486
 Philadelphia
 chromosome-positive
 leukemias
 treatment of, 360–65
 Phosphatases
 protein kinases and,
 725–27
 Piloty's acid, 343–44
 Pioglitazone, 195, 196
 Piperaquine
 malaria and, 576
 Pirfenidone (PD), 673–74
 Pitavastatin, 90, 91, 706–8
 Plaque stability
 statins and, 99, 103, 108
 Plasmalemmal caveolae
 cell signaling, 591–98
 Plasmodium, 565, 572, 573
 Platelet-derived growth factor
 receptor (PDGFR)
 cancer therapy and, 357,
 358, 360, 375
 cell signaling and, 594
 dermatofibrosarcoma
 protuberans and, 367
 mast cell disease and, 370
 solid tumors and, 376
 Platelet function
 statins and, 98, 108
 Polymerase chain resection
 (PCR), 630, 631, 648
 Polymorphisms
 in cytosolic glutathione
 transferases (GSTs), 51,
 66–68
 Polyubiquitin
 26S proteasome and,
 444–45
 Polyubiquitinated proteins
 proteasomal system and,
 442–43, 445
 Polyubiquitination
 cellular, 440–42
 explained, 440
 P450, 440–57
 Porter, Todd, 10–11
 Positron emission
 tomography (PET)
 drug studies and, 234
 gastrointestinal stromal
 tumors (GIST) and,
 368–69
 Pravastatin, 90–92, 107,
 706–8
 Pravastatin
 Inflammation/CRP
 Evaluation (PRINCE)
 study, 100
 Pregnancy
 arachidonic acid
 ω -hydroxylation and, 413,
 429
 CYP4A expression and,
 421
 Prelog, Vladimir, 4
 Probenecid, 710
 Procainamide, 645–46
 Procaine, 645–46
 Progesterone
 glutathione transferases
 (GSTs) and, 51, 58
 Program on the Surgical
 Control of the
 Hyperlipidemias
 (POSCH), 106
 Proguanil
 malaria and, 571–72,
 574–76
 Prospective Study of
 Pravastatin in the Elderly
 at Risk (PROSPER), 104
 Prostaglandins (PGD), 51, 52,
 58–60, 76
 hepatic fibrosis and, 617
 Proteasomal degradation
 P450 ubiquitination and,
 451–52
 Proteasomal system
 polyubiquitinated proteins
 and, 442–43, 445
 Proteasome
 cancer therapy and, 467–68
 20S, 442–44
 26S, 439–40, 442–47,
 449–52, 467
 Proteasome inhibitors (PIs)
 cancer and, 465–73
 Protein(s)
 cell signaling and, 588–91,
 593
 CFS, 233

- isoprenylated
 - statins and, 92–95, 108
- kinases
 - phosphatases and, 725–27
- modifications
 - hepatotoxicity and, 177, 180
- scaffolding
 - cell signaling and, 590
- solid tumors and, 376
- synthesis
 - inhibitors of, 537–38
- ubiquitin-proteasome pathway (UBP) and, 465–67, 473
- Proteomics, 228
 - drug-target interactions and, 232–33
- Prothionamide (PTH), 531, 534–36
- Proximal cyclopropanation of
 - alpha-mycolates (PcaA), 544
- PS-341
 - bortezomib and, 465
 - myeloma treatment with, 465–73
- Psychiatry
 - research, 228
- Psychological effects
 - of statins, 105
- Puerarin, 218
- Pyrazinamide (PAZ), 192, 531–35, 538, 539, 549–51
- Pyrazinoic acid (POA), 538
- Pyrimethamine
 - pyrimethamine/sulfadoxine malaria and, 565, 572–74
- Q**
 - Quantitative structure-activity relationship (QSAR), 477
 - CYP2C9 inhibitors
 - and, 480
 - Quinidine, 575, 708–9
 - Quinine, 575, 708–9
 - antimalarial agents and, 567
 - Quinolines
 - malaria and, 567–69
 - Quinolone drugs
 - tuberculosis (TB) treatment and, 532, 535
 - R**
 - Rac
 - cardiac hypertrophy and, 101
 - statins and, 92–93, 97
 - Raf
 - cell signaling and, 589–90
 - Rap
 - cardiac hypertrophy and, 101
 - Ras
 - cardiac hypertrophy and, 101
 - cell signaling and, 589–90
 - statins and, 92–93, 98
 - Reactive oxygen species (ROS)
 - statins and, 96
 - Renal cell carcinoma
 - bortezomib and, 472
 - Renal drug excretion
 - mechanism of, 690–91
 - Renal function
 - arachidonic acid
 - ω -hydroxylases and, 413–29 passim
 - Renal transport
 - of drugs, 689–711
 - Renin-angiotensin system (RAS), 666, 668–69
 - Rensheng, 217
 - Resistin, 131, 134
 - adipocytes and, 129–30
 - Restriction landmark
 - genomic scanning (RLGS) technique, 641
 - Resveratrol
 - antifibrotic properties, 615
 - Retinoblastoma (Rb) gene(s), 630
 - Retinoblastoma (Rb) tumor suppressor protein, 737
 - Rho
 - cardiac hypertrophy and, 101
 - statins and, 92–95, 98, 106, 108
 - Rifalazil (RLZ), 539–40
 - Rifampicin, 192
 - Rifampin (RIF), 530–35, 537, 539
 - CYP2C9 and, 486
 - Rifamycin
 - new derivatives, 539–40
 - Riminophenazine, 541
 - Ritonavir
 - garlic and, 212
 - Rose, William C., 2–3
 - Rosiglitazone, 195, 196
 - Rosuvastatin, 90–92
 - S**
 - Sabbatical leaves, 4
 - Sage, 217
 - Saquinavir
 - garlic and, 212–13
 - Sarcomas
 - imatinib mesylate and, 376
 - Scandinavian Simvastatin Survival Study, 89
 - Schizophrenia
 - adenosine receptors and, 398
 - proteomic approaches to, 233
 - Secreted frizzled-related proteins (SFRPs), 637, 639
 - Seizures
 - adenosine and, 400
 - Sevoflurane
 - Compound A and, 147–48, 157–66

- Sho-saiko-to, 218
antifibrotic properties, 615
- Sigma factors
tuberculosis (TB) and, 545
- Signal transduction
cell signaling and, 596-98
- Signal transduction inhibitors
(STI), 359, 514, 515
- Signaling networks
living cells and, 587-98
- Signaling unit
organization of a, 588-91
- Simvastatin, 90-92
- Sleep
adenosine and, 393-95
- S-methylcytosine (5mC),
630-32, 635, 636, 647
- Smooth muscle proliferation
statins and, 97-98, 108
- Soda lime
anesthetic agents and, 169
2-bromo-2-chloro-1,1-
difluoroethylene and,
157
generation of carbon
monoxide and, 166-67
trichloroethylene and,
152
- Sodium bisulfite, 630
- Sodium carbonate
isolating caveolae and,
592-93
- Spices
CYP enzymes and, 217
- Spironolactone, 669
- St. John's wort
antibiotics and, 213
clinical studies of, 219
drug disposition and,
216-17
labeling information,
207-8
stability, 211
tinctures of, 210
- Statin(s), 89-108, 705-8
cardiac hypertrophy and,
101-2
clinical trials with, 89-90,
105-8
dementia and, 104-5
endothelial function and,
95-96
endothelial progenitor cells
(EPCs), 96-98, 103
ischemic stroke and, 102-3
isoprenylated proteins and,
92-95, 108
myocardium and, 101-2
pharmacokinetic properties
of, 90-92
plaque stability and, 99,
103, 108
platelet function, 98, 108
pleiotropy, 105-8
potential utility in heart
failure, 670
psychological effects of,
105
smooth muscle
proliferation and, 97-98,
108
vascular inflammation and,
99-101, 108
- Steroid hormones
glutathione transferases
(GSTs) and, 51, 58
- STI 571
See Imatinib mesylate
- Streptomycin (SM), 531,
533-35, 537-38
- Striatum
dopamine and, 395-98
- Strobel, Henry, 6
- Stroke, 280-81
ischemic
cholesterol levels and,
102-3
statins and, 102-3
- Subsite specificity
neonicotinoids and, 259-61
- Sudden cardiac death (SCD),
664, 669
- Sulfa drugs
treatment of tuberculosis
(TB) by, 530-32
- Sulfadoxine
pyrimethamine/sulfadoxine
malaria and, 565,
572-74
- Sulfamethoxazole (SMX), 28,
37
- Sulfonamide
malaria and, 565, 571-74
- Suppressor of cytokine
signaling (SOCS), 640
- Swiss Federal Institute of
Technology, 4
- Symposium on Microsomes
and Drug Oxidations,
6-8
- Synaptic transmission
adenosine and, 389-90
- T**
- T cells
pathogenesis of hepatocyte
injury and, 189, 191
- Tamoxifen, 181
metabolic bioactivation of,
182
- TarcevaTM, 373-74
- Teas
herbal
drug metabolizing
enzymes and, 215
evaluation of, 210
- TER286, 55
- Testosterone
binding sites, 300
glutathione transferases
(GSTs) and, 51, 58
- Tetracyanonickelate, 344
- Tetrahydroaminoacridine
(THA), 279
- Tetrahydrofolate
antimalarial drugs and,
572, 573
- TGF- β
See Transforming growth
factor (TGF)- β
- Thiaclopid, 247-61 *passim*

- Thiamethoxam, 247–61
passim
- Thiazolidinedione
antidiabetics, 194–95
- Thiols
nitroxyl (HNO) and,
340–41, 344, 346, 347
- Threonine, 2
- Thrombosis, 99
C-reactive protein
(hs-CRP) and, 100
- Thromboxane A₂ (TXA₂), 98
- Thrombus formation
statins and, 98
- Thyme, 217
- Tinctures
herbal, 210
- Tissue inhibitor of
metalloproteinase (TIMP)
hepatic fibrosis and, 609,
610
TIMP-1, 617
- TLK286, 55
- TNF- α
See Tumor necrosis
factor- α (TNF- α)
- Tolbutamide, 478–80
- Toxicity
2-bromo-2-chloro-1,1-
difluoroethylene and,
155–57
carbon monoxide, 167–69
Compound A and, 162–66
rationally targeted agent
and, 376
sevoflurane and, 158
trichloroethylene and, 148,
149, 151–52
- Toxicology
neonicotinoid, 250–53
- Traditional medicine(s)
(TMs)
contaminated, 204–5
in developing countries,
204
plants, 217–19
- Tranilast, 674
- Transcriptional regulation
histone deacetylase
(HDAC) inhibitors
and, 496–98
- Transcriptional repression,
634
histone deacetylase
(HDAC) inhibitors and,
505–9
- Transcriptional silencing
tumor suppressor genes and,
634, 638, 647
- Transforming growth factor
(TGF)- β
antifibrotic therapy and,
671
hepatic fibrosis and,
613–15
- Transporters
drug-drug interaction and,
689–711
hepatobiliary drug
excretion and, 691–92
kidney, 693–95
liver, 695–97
renal drug excretion and,
690–91
- Trastuzumab
breast cancer and, 371–73
- Trichloroethylene
dichloroacetylene and,
147–52
- Trichloropropene oxide,
319–20
- Trigeminal nerve
trichloroethylene and, 148,
152
- Triton X-100
isolating caveolae and,
592–93
- Troglitazone, 194–95
bioactivation of, 196
- Tuberculosis (TB), 529–51
drugs, 533–38
genomics and drug targets,
548
new drug targets, 542–48
- Tuberculosis Antimicrobial
Acquisition &
Coordinating Facility
(TAACF), 549
- Tumeric, 217
- Tumor(s)
behavior
marker for, 644
bortezomib and, 472
DSPase regulation and,
737
EGFR and, 359, 371
histone deacetylase
(HDAC) inhibitors and,
503–17
paradigm shift in treating,
376
rationally targeted agent
and, 376
See also Tumor suppressor
gene(s); Tumorigenesis
- Tumorigenesis
glutathione transferases
(GSTs) and, 75
See also Tumor(s)
- Tumor necrosis factor- α
(TNF- α), 134
adipose tissue, 130, 131
heart failure therapy and,
671
hepatic stellate cells and,
609
lipolysis and, 125
- Tumor suppressor gene(s),
630, 631, 634, 646, 648
silencing, 634–40, 646–48
See also Tumor(s)
- 26S proteasome, 439–40,
442–47, 449–52
- Two-component systems
tuberculosis (TB) and, 546
- Type 2 diabetes
See Diabetes
- Tyrosine kinase inhibitors,
357–77
development of, 359–60
- Tyrosine kinases

- cell signaling and, 593–94
 malignancies and, 359
 structure and function of, 358–59, 375
- U**
- Ubiquitin-proteasome pathway (UBP)
 protein degradation and, 465–67, 473
- Ubiquitination
 cytochrome P450, 439–57
 explained, 439–40
 protein, 466–67
- Ubiquitylation
 explained, 439–40
- Ueda, Tetsufumi, 5
- United Kingdom General Practice Research Database, 104, 105
- United States
 herbal products (HPs) and, 204
- University of Chicago, 2
- University of Colorado, 1–2
- University of Illinois
 M.J. Coon at, 2–3
- University of Michigan
 M.J. Coon at, 4
- University of Pennsylvania
 M.J. Coon at, 3–4
- V**
- Valerian root, 205
 labeling information, 207–8
- Valpromide, 320
- Vascular endothelial growth factor (VEGF)
 cancer therapy and, 358, 375
 cell signaling and, 594
- Vascular inflammation
 statins and, 99–101, 108
- Vascular system
 anticancer therapy and, 374
- VEGF
 See Vascular endothelial growth factor (VEGF)
- Velcade™
 See PS-341/bortezomib
- Verapamil
 metabolism of, 298
- Virulence factors
 tuberculosis (TB) and, 545
- Volume transmission (VT), 231
- Von Hippel-Lindau (VHL) gene, 630
- W**
- Warfarin, 484–85
 benzbromarone and, 481
 cranberry juice and, 212
 CYP2C9 and, 478–84
- Weight loss
 “magic bullet,” 137
- West of Scotland Coronary Prevention Study (WOSCOPS), 89, 107
- White adipose tissue (WAT), 119–20
- White fat cells
 afferent messages
 controlling, 121–26
- Wilson, D. Wright, 3
- Wiring transmission (WT), 231
- Wu-chu-yu-tang, 218–19
- X**
- Xenobiotics
 glutathione transferases (GSTs) and, 54–55
- Z**
- Zinc
 ampicillin and, 213
- Zinc- α_2 -P-glycoprotein (ZAG), 125–26

CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 41-45

A

Abdel-Rahman SM,
44:111-36
Adams JP, 42:135-63
Allio T, 43:125-47
Altman RB, 42:113-33
Ambler SK, 45:657-87
Anders MW, 45:147-76
Anderson RGW, 45:587-603
Anderson KC, 45:465-76
Angers S, 42:409-35
Arav-Boger R, 45:565-85
Arnason JT, 45:203-26
Aschner M, 44:87-110
Atkins WM, 45:291-310
Atkinson AJ Jr, 41:347-66
Aweeka F, 44:499-523

B

Bagdassarian CK, 41:661-90
Baldwin LA, 43:175-97
Bale TL, 44:525-58
Barber DL, 42:527-52
Barnes PJ, 42:81-98
Bearss DJ, 43:359-79
Benz CC, 45:495-528
Bertaccini E, 41:23-51
Besirli CG, 44:451-74
Beutler B, 43:609-28
Bicknell R, 44:219-38
Bieck PR, 45:227-46
Blaschke TF, 44:499-523
Bode-Böger SM, 41:79-99
Böger RH, 41:79-99
Blakely RD, 43:521-44
Boekelheide K, 43:125-47
Bogdanffy MS, 43:485-520
Bolt HM, 43:485-520
Bortner CD, 42:259-81

Bouvier M, 42:409-35
Brady AE, 44:559-609
Breyer MD, 41:661-90
Breyer RM, 41:661-90
Briggs CJ, 45:203-26
Brown RD, 45:657-87
Brunton LL, 41:751-73
Burke MD, 41:297-316

C

Calabrese EJ, 43:175-97
Carlsson A, 41:237-60
Carlsson ML, 41:237-60
Caro AA, 44:27-42
Caron MG, 43:261-84
Casida JE, 45:247-68
Cederbaum AI, 44:27-42
Chan PLS, 41:625-59
Chauhan D, 45:465-76
Chen J-F, 45:385-412
Chun J, 41:507-34
Chuang D-M, 45:269-90
Cidlowski JA, 42:259-81
Claiborne A, 44:325-47
Clancy CE, 43:441-61
Colamarino SA, 44:399-421
Coles P, 41:175-202
Collins S, 44:297-323
Conney AH, 43:1-30
Contos JJA, 41:507-34
Coon MJ, 45:1-25
Correia MA, 45:439-64
Costa LG, 44:87-110
Coyle JT, 42:165-79

D

Davis KL, 41:203-36
de Boer AG, 43:629-56
Defer N, 41:145-74

de Groat WC, 41:691-721
Denhardt DT, 41:723-49
Denison MS, 43:309-34
Denker SP, 42:527-52
Ding X, 43:149-73
Doull J, 41:1-21
Drummond DC, 45:495-528
DuBois RN, 42:55-80
Ducruet AP, 45:725-50

E

Eichelbaum M, 43:285-307
Elsayed Y, 43:199-231
Embree-Ku ME, 43:125-47
Esteller M, 45:629-56
Eudy JD, 42:181-208
Evans WE, 41:101-21

F

Fernandez EJ, 42:469-99
Finnell RH, 42:181-208
Fisone G, 44:269-96
Flanagan JU, 45:51-88
Fleming SL, 43:125-47
Foster BC, 45:203-26
Fredholm BB, 45:385-412
Fromm MF, 43:285-307
Fukushima N, 41:507-34
Fukuto JM, 45:335-55
Fung H-L, 44:67-85

G

Gage FH, 44:399-421
Gaillard PJ, 43:629-56
Gainetdinov RR, 43:261-84
Gandhi M, 44:499-523
Gelineau-van Waes J,
42:181-208
Giachelli CM, 41:723-49

Girault J-A, 44:269-96
 Giri SN, 43:73-95
 Gold MS, 44:371-97
 Golding BT, 42:325-48
 Goodman JI, 42:501-25
 Goodwin B, 42:1-23
 Greenblatt RM, 44:499-523
 Greengard P, 44:269-96
 Greenlee WF, 41:297-316
 Grenard P, 45:605-28
 Griffin RJ, 42:325-48
 Guengerich FP, 45:27-49
 Guo Z, 45:495-528
 Guyton KZ, 41:421-42

H

Hall SJ, 43:125-47
 Hammock BD, 45:311-33
 Hanoune J, 41:145-74
 Hardcastle IR, 42:325-48
 Harris AL, 44:219-38
 Harris RA, 41:23-51
 Hayes JD, 45:51-88
 Hengstler JG, 43:485-520
 Hickson ID, 41:367-401
 Hideshima T, 45:465-76
 Highfield Nickols H,
 44:559-609
 Hogg N, 42:585-600
 Holbro T, 44:195-217
 Holford NHG, 41:625-59
 Holm-Waters S, 41:237-60
 Hook SS, 41:471-505
 Hough C, 45:269-90
 Hunter JC, 44:371-97
 Hurley LH, 43:359-79
 Hynes NE, 44:195-217

I

Ignarro LJ, 43:97-123
 Insel PA, 41:593-624
 Ishii I, 41:507-34

J

Javitch JA, 42:437-67
 Johnson EM Jr, 44:451-74
 Johnson KJ, 43:125-47
 Jones JP, 45:477-94

Jowsey IR, 45:51-88
 Juliano RL, 42:283-323
 Julien B, 45:605-28
 Jupe SC, 44:43-66

K

Kamendulis LM, 44:239-67
 Kaminsky LS, 43:149-73
 Karplus PA, 44:325-47
 Kass RS, 43:441-61
 Kauffman RE, 44:111-36
 Kedzierski RM, 41:851-76
 Keefer LK, 43:585-607
 Kenakin T, 42:349-79
 Kensler TW, 41:421-42
 Kim D, 45:27-49
 Kim G, 43:199-231
 Kim RB, 41:815-50;
 44:137-66
 Kinsel JF, 43:463-84
 Kirpotin DB, 45:495-528
 Kitteringham NR, 41:443-70;
 45:177-202
 Klaunig JE, 44:239-67
 Klein PS, 41:789-813
 Klein TE, 42:113-33
 Kliever SA, 42:1-23
 Kootstra NA, 43:413-39
 Kroetz DL, 45:413-38
 Kurokawa J, 43:441-61
 Kurzrock R, 45:357-84
 Kwon EJ, 43:125-47

L

Lafontan M, 45:119-46
 Lai J, 44:371-97
 Laufs U, 45:89-118
 Lazo JS, 45:725-50
 Lebedeva I, 41:403-19
 Lee HC, 41:317-45
 Lee SJ, 41:569-91
 Lee W, 44:137-66
 Lesko LJ, 41:347-66
 Li T-K, 41:53-77
 Liao JK, 45:89-118
 Lie DC, 44:399-421
 Liggett SB, 43:381-411
 Limbird LE, 44:559-609

Lin JH, 41:535-67
 Linden J, 41:775-87
 Liu LF, 41:53-77
 Liu X, 44:349-70
 Lolis E, 42:469-99
 Long CS, 45:657-87
 Lotersztajn S, 45:605-28
 Lu AYH, 41:535-67

M

Mackenzie PI, 44:1-25
 Maggs JL, 45:177-202
 Maliakal P, 42:25-54
 Mallat A, 45:605-28
 Marnett LJ, 42:55-80
 Martin E, 41:203-36
 Martin TL, 44:297-323
 Masino SA, 45:385-412
 McCammon AJ, 43:31-45
 McEwen BS, 41:569-91
 McGraw DW, 43:381-411
 McKinnon RA, 44:1-25
 McLeod HL, 41:101-21
 Means AR, 41:471-505
 Melvin WT, 41:297-316
 Meng X, 42:25-54
 Michel JJ, 42:235-57
 Miners JO, 44:1-25
 Ming G-I, 44:399-421
 Miranda KM, 45:335-55
 Mitchell MD, 45:657-87
 Möhler H, 44:475-98
 Monga M, 43:199-231
 Montfort WR, 41:261-95
 Morisseau C, 45:311-33
 Mundo-Paredes E, 45:439-64
 Murad F, 41:203-36
 Murray GI, 41:297-316
 Myers SA, 41:661-90

N

Nagy SR, 43:309-34
 Nairn AC, 44:269-96
 Napoli C, 43:97-123
 Nass R, 43:521-44
 Negishi M, 41:123-43
 Nemeroff CB, 41:877-906
 Neu J, 42:381-408

Nguyen T, 43:233-60
 Nilsson M, 41:237-60
 Nishi A, 44:269-96
 Noble CO, 45:495-528
 Norbury CJ, 41:367-401

O

Oesch F, 43:485-520
 O'Neill PM, 41:443-70
 Owens MJ, 41:877-906

P

Park BK, 41:443-70;
 45:177-202
 Patel SR, 43:125-47
 Petralia RS, 43:335-58
 Phiel CJ, 41:789-813
 Pickett CB, 43:233-60
 Pirmohamed M, 45:177-202
 Poole LB, 44:325-47
 Pootoolal J, 42:381-408
 Porreca F, 44:371-97
 Posner GH, 41:421-42
 Potter WZ, 45:227-46
 Powis G, 41:261-95
 Prybylowski K, 43:335-58
 Putney LK, 42:527-52

R

Rana BK, 41:593-624
 Rasoulpour RJ, 43:125-47
 Redinbo MR, 42:1-23
 Rees S, 44:43-66
 Rettie AE, 45:477-94
 Rezler EM, 43:359-79
 Rittling SR, 41:723-49
 Robidoux J, 44:297-323
 Rosenquist TH, 42:181-208
 Rudolph U, 44:475-98

S

Sadeghi S, 45:439-64
 Salahpour A, 42:409-35
 Sans N, 43:335-58
 Sato H, 45:689-723
 Sausville EA, 43:199-231

Schnellmann RG, 44:349-70
 Schenk D, 43:545-84
 Schoenfeld HA, 43:125-47
 Schwab M, 43:285-307
 Scott GK, 45:495-528
 Scott JD, 42:235-57
 Selkoe DJ, 43:545-84
 Senatorov VV, 45:269-90
 Shapiro TA, 45:565-85
 Sherratt PJ, 43:233-60
 Shi L, 42:437-67
 Shiina T, 41:593-624
 Shitara Y, 45:689-723
 Shoham M, 41:175-202
 Simpson LL, 44:167-93
 Small KM, 43:381-411
 Smith PA, 44:1-25
 Soldin OP, 44:87-110
 Song H, 44:399-421
 Sorich MJ, 44:1-25
 Standly S, 43:335-58
 Stein CA, 41:403-19
 Stein CM, 41:815-50
 Steinberg SF, 41:751-73
 Stout SC, 41:877-906
 Straus SE, 43:463-84
 Sueyoshi T, 41:123-43
 Sugiyama Y, 45:689-723
 Svenningsson P, 44:269-96
 Svensson CI, 42:553-83
 Sweatt JD, 42:135-63
 Switzer CH, 45:335-55
 Syversen T, 44:87-110

T

Tan CM, 44:559-609
 Tateyama M, 43:441-61
 Taylor SL, 42:99-112
 Tedroff J, 41:237-60
 Teixeira-Clerc F, 45:605-28
 Thibonnier A, 41:175-202
 Thibonnier M, 41:175-202
 Thompson S, 43:125-47
 Tibes R, 45:357-84
 Tomizawa M, 45:247-68
 Trent J, 45:357-84

Trudell JR, 41:23-51
 Tsai G, 42:165-79
 Turko IV, 41:203-36

V

Vale WW, 44:525-58
 van der Sandt ICI, 43:629-56
 Van Vleet T, 44:349-70
 Vaugeois J-M, 45:385-412
 Verma IM, 43:413-39
 Vitalone A, 44:87-110
 Vogt A, 45:725-50

W

Wang LH, 44:451-74
 Wang Q, 44:559-609
 Waters N, 41:237-60
 Watson RE, 42:501-25
 Wehrens XHT, 43:441-61
 Wei L-N, 43:47-72
 Weiner JA, 41:507-34
 Wenthold RJ, 43:335-58
 Wess J, 44:423-50
 White MA, 45:587-603
 Williams DP, 45:177-202
 Wink DA, 45:335-55
 Wipf P, 45:725-50
 Wise A, 44:43-66
 Wong CF, 43:31-45
 Wood AJJ, 41:815-50
 Wright GD, 42:381-408

X

Xie H-G, 41:815-50
 Xu F, 45:413-38

Y

Yaksh TL, 42:553-83
 Yamakura T, 41:23-51
 Yanagisawa M, 41:851-76
 Yang CS, 42:25-54
 Yoshimura N, 41:691-721

Z

Zhang Y, 45:529-64
 Zhang Z-Y, 42:209-34

CHAPTER TITLES, VOLUMES 41-45

Prefatory

PHARMACOLOGY

Cytochrome P450: Nature's Most Versatile Biological Catalyst	MJ Coon	45:1-25
---	---------	---------

TOXICOLOGY

Toxicology Comes of Age	J Doull	41:1-21
Induction of Drug-Metabolizing Enzymes: A Path to the Discovery of Multiple Cytochromes P450	AH Conney	43:1-30

General Topics in Pharmacology and Toxicology

Hormesis: The Dose-Response Revolution	EJ Calabrese, LA Baldwin	43:175-97
Regulatory Mechanisms Controlling Gene Expression Mediated by the Antioxidant Response Element	T Nguyen, PJ Sherratt, CB Pickett	43:233-60
Voltage-Gated Sodium Channels and Hyperalgesia	J Lai J, F Porreca, JC Hunter, MS Gold	44:371-97

RECEPTORS

Lysophospholipid Receptors	N Fukushima, I Ishii, JJ Contos, JA Weiner, J Chun	41:507-34
Genetic Variations and Polymorphisms of G Protein-Coupled Receptors: Functional and Therapeutic Implications	BK Rana, T Shiina, PA Insel	41:593-624
Prostanoid Receptors: Subtypes and Signaling	RM Breyer, CK Bagdassarian, SA Myers, MD Breyer	41:661-90
Role of Osteopontin in Cellular Signaling and Toxicant Injury	DT Denhardt, CM Giachelli, SR Rittling	41:723-49

Molecular Approach to Adenosine Receptors: Receptor-Mediated Mechanisms of Tissue Protection	J Linden	41:775-87
Glutamatergic Mechanisms in Schizophrenia	G Tsai, JT Coyle	42:165-79
Drug Efficacy at G Protein-Coupled Receptors	T Kenakin	42:349-79
Dimerization: An Emerging Concept for G Protein-Coupled Receptor Ontogeny and Function	S Angers, A Salahpour, M Bouvier	42:409-35
The Binding Site of Aminergic G Protein-Coupled Receptors: The Transmembrane Segments and Second Extracellular Loop	L Shi, JA Javitch	42:437-67
Retinoid Receptors and Their Coregulators	L-N Wei	43:47-72
Trafficking of NMDA Receptors	RJ Wenthold, K Prybylowski, S Standly, N Sans, RS Petralia	43:335-58
The Identification of Ligands at Orphan G-Protein Coupled Receptors	A Wise, SC Jupe, S Rees	44:43-66
ErbB Receptors: Directing Key Signaling Networks Throughout Life	T Holbro, NE Hynes	44:195-217
Voltage-Gated Sodium Channels and Hyperalgesia	J Lai J, F Porreca, JC Hunter, MS Gold	44:371-97
Membrane Trafficking of G Protein-Coupled Receptors	CM Tan, AE Brady, H Highfield Nickols, Q Wang, LE Limbird	44:559-609
Actions of Adenosine at Its Receptors in the CNS: Insights from Knockouts and Drugs	BB Fredholm, J-F Chen, SA Masino, J-M Vaugeois	45:385-412

RENAL SYSTEM

Pharmacology of the Lower Urinary Tract	WC de Groat, N Yoshimura	41:691-721
---	-----------------------------	------------

SIGNAL TRANSDUCTION

Physiological Functions of Cyclic ADP-Ribose and NAADP as Calcium Messengers	HC Lee	41:317-45
Cellular Mechanisms for the Repression of Apoptosis	CD Bortner, JA Cidlowski	42:259-81
Protein Sulfenic Acids in Redox Signaling	LB Poole, A Karplus, A Claiborne	44:325-47
Signaling Networks in Living Cells	MA White, RGW Anderson	45:587-603

SYNAPTIC FUNCTIONS

Molecular Psychology: Roles for the ERK MAP Kinase Cascade in Memory	JP Adams, JD Sweatt	42:135-63
Identification of the Major Steps in Botulinum Toxin Action	LL Simpson	44:167-93
DARPP-32: An Integrator of Neurotransmission	P Svenningsson, A Nishi, G Fisone, J-A Girault, AC Nairn, P Greengard	44:269-96
Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications	J Wess	44:423-50

ION CHANNELS

Voltage-Gated Sodium Channels and Hyperalgesia	J Lai, F Porreca, JC Hunter, MS Gold	44:371-97
---	--	-----------

TRANSPORTERS

Compartmentation of G Protein-Coupled Signaling Pathways in Cardiac Myocytes	SF Steinberg, LL Brunton	41:751-73
AKAP-Mediated Signal Transduction	JJC Michel, JD Scott	42:235-57
The Changing Face of the Na ⁺ /H ⁺ Exchanger, NHE1: Structure, Regulation, and Cellular Actions	LK Putney, SP Denker, DL Barber	42:527-52
Monoamine Transporters: From Genes to Behavior	RR Gainetdinov, MG Caron	43:261-84

Genetic Polymorphisms of the Human MDR1 Drug Transporter	M Schwab, M Eichelbaum, MF Fromm	43:285-307
The <i>Caenorhabditis elegans</i> Dopaminergic System: Opportunities for Insights into Dopamine Transport and Neurodegeneration	R Nass, RD Blakely	43:521-44
The Role of Drug Transporters at the Blood-Brain Barrier	AG de Boer, ICJ van der Sandt, PJ Gaillard	43:629-56
ENZYMES		
Tumor Cell Death Induced by Topoisomerase-Targeting Drugs	T-K Li, LF Liu	41:53-77
Phenobarbital Response Elements of Cytochrome P450 Genes and Nuclear Receptors	T Sueyoshi, M Negishi	41:123-43
Regulation and Role of Adenylyl Cyclase Isoforms	J Hanoune, N Defer	41:145-74
Regulation of CYP3A Gene Transcription by the Pregnane X Receptor	B Goodwin, MR Redinbo, SA Kliewer	42:1-23
Protein Allergenicity Assessment of Foods Produced Through Agricultural Biotechnology	SL Taylor	42:99-112
The Biochemistry and Physiology of S-Nitrosothiols	N Hogg	42:585-600
Telomere Inhibition and Telomere Disruption as Processes for Drug Targeting	EM Rezler, DJ Bearss, LH Hurley	43:359-79
The Role of Calpain in Oncotic Cell Death	X Liu, T Van Vleet, RG Schnellmann	44:349-70
Mixed-Lineage Kinases: A Target for the Prevention of Neurodegeneration	LH Wang, CG Besirli, EM Johnson Jr.	44:451-74
Glutathione Transferases	JD Hayes, JU Flanagan, IR Jowsey	45:51-88
Non-Michaelis-Menten Kinetics in Cytochrome P450-Catalyzed Reactions	WM Atkins	45:291-310

Clinical Development of Histone Deacetylase Inhibitors	DC Drummond, CO Noble, DB Kirpotin, Z Guo, GK Scott, CC Benz	45:495-528
Evaluation of Drug-Drug Interaction in the Hepatobiliary and Renal Transport of Drugs	Y Shitara, H Sato, Y Sugiyama	45:689-723
CHEMICAL AGENTS		
The Clinical Pharmacology of L-Arginine	RH Böger, SM Bode-Böger	41:79-99
The Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor Antagonists	M Thibonnier, P Coles, A Thibonnier, M Shoham	41:175-202
Novel Effects of Nitric Oxide	KL Davis, E Martin, IV Turko, F Murad	41:203-36
Inhibition of Carcinogenesis by Tea	CS Yang, P Maliakal, X Meng	42:25-54
Nitric Oxide-Releasing Drugs	C Napoli, LJ Ignarro	43:97-123
2,5-Hexandione-Induced Testicular Injury	K Boekelheide, SL Fleming, T Allio, ME Embree-Ku, SJ Hall, KJ Johnson, EJ Kwon, SR Patel, RJ Rasoulpour, HA Schoenfeld, S Thompson	43:125-47
Progress Toward Clinical Application of the Nitric Oxide-Releasing Diazeniumdiolates	LK Keefer	43:585-607
Nitroxyl (HNO): Chemistry, Biochemistry, and Pharmacology	JM Fukuto, CH Switzer, KM Miranda, DA Wink	45:335-55
PEPTIDES AND PROTEINS		
Protein Allergenicity Assessment of Foods Produced Through Agricultural Biotechnology	SL Taylor	42:99-112

BIOTRANSFORMATION

Metabolism of Fluorine-Containing Drugs	BK Park, NR Kitteringham, PM O'Neill	41:443-70
Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes	JH Lin, AYH Lu	41:535-67
Regulation of CYP3A Gene Transcription by the Pregnane X Receptor	B Goodwin, MR Redinbo, SA Kliewer	42:1-23
Human Extrahepatic Cytochromes P450: Function in Xenobiotic Metabolism and Tissue-Selective Chemical Toxicity in the Respiratory and Gastrointestinal Tracts	X Ding, LS Kaminsky	43:149-73
Predicting Human Drug Glucuronidation Parameters: Application of In Vitro and In Silico Modeling Approaches	JO Miners, PA Smith, MJ Sorich, RA McKinnon, PI Mackenzie	44:1-25
Oxidative Stress, Toxicology, and Pharmacology of CYP2E1	AA Caro, AI Cederbaum	44:27-42
Cytochrome P450 Activation of Arylamines and Heterocyclic Amines	D Kim, FP Guengerich	45:27-49
Formation and Toxicity of Anesthetic Degradation Products	MW Anders	45:147-76
The Role of Metabolic Activation in Drug-Induced Hepatotoxicity	BK Park, NR Kitteringham, JL Maggs, M Pirmohamed, DP Williams	45:177-202
Epoxide Hydrolases: Mechanisms, Inhibitor Designs, and Biological Roles	C Morisseau, BD Hammock	45:311-33
Tyrosine Kinase Inhibitors and the Dawn of Molecular Cancer Therapeutics	R Tibes, J Trent, R Kurzrock	45:357-84
Cytochrome P450 Ubiquitination: Branding for the Proteolytic Slaughter?	MA Correia, S Sadeghi, E Mundo-Paredes	45:439-64
Clinical and Toxicological Relevance of CYP2C9: Drug-Drug Interactions and Pharmacogenetics	AE Rettie, JP Jones	45:477-94

NUCLEIC ACIDS

- | | | |
|---|---------------------------|------------|
| Cellular Responses to DNA Damage | CJ Norbury,
ID Hickson | 41:367-401 |
| Ca ²⁺ /CaM-Dependent Kinases: From
Activation to Function | SS Hook, AR Means | 41:471-505 |

PHARMACOKINETICS/TOXICOKINETICS

- | | | |
|---|--|------------|
| The Integration of Pharmacokinetics and
Pharmacodynamics: Understanding
Dose-Response | SM Abdel-Rahman,
RE Kauffman | 44:111-36 |
| Transporters and Renal Drug Elimination | W Lee, RB Kim | 44:137-66 |
| Natural Health Products and Drug
Disposition | BC Foster,
JT Arnason,
CJ Briggs | 45:203-26 |
| Evaluation of Drug-Drug Interaction in the
Hepatobiliary and Renal Transport of
Drugs | Y Shitara, H Sato,
Y Sugiyama | 45:689-723 |

CANCER AND CARCINOGENESIS

- | | | |
|--|---|------------|
| Properties and Biological Activities of
Thioredoxins | G Powis,
WR Montfort | 41:261-95 |
| Cancer Chemoprevention Using Natural
Vitamin D and Synthetic Analogs | KZ Guyton,
TW Kensler,
GH Posner | 41:421-42 |
| Inhibition of Carcinogenesis by Tea | CS Yang, P Maliakal,
X Meng | 42:25-54 |
| COX-2: A Target for Colon Cancer
Prevention | LJ Marnett,
RN DuBois | 42:55-80 |
| Glycopeptide Antibiotic Resistance | J Pootoolal, J Neu,
GD Wright | 42:381-408 |
| Altered DNA Methylation: A Secondary
Mechanism Involved in Carcinogenesis | JJ Goodman,
RE Watson | 42:501-25 |
| Signal Transduction-Directed Cancer
Treatments | EA Sausville,
Y Elsayed,
M Monga, G Kim | 43:199-231 |
| The Role of Oxidative Stress in
Carcinogenesis | JE Klaunig,
LM Kamendulis | 44:239-67 |

- | | | |
|---|---|-----------|
| Proteasome Inhibition in Multiple
Myeloma: Therapeutic Implication | D Chauhan,
T Hideshima,
KC Anderson | 45:465-76 |
|---|---|-----------|

- | | | |
|--|------------|-----------|
| Aberrant DNA Methylation as a
Cancer-Inducing Mechanism | M Esteller | 45:629-56 |
|--|------------|-----------|

- | | | |
|---|--|-----------|
| Dual Specificity Protein Phosphatases:
Therapeutic Targets for Cancer and
Alzheimer's Disease | AP Ducruet, A Vogt,
P Wipf, JS Lazo | 45:725-50 |
|---|--|-----------|

CLINICAL THERAPEUTICS

- | | | |
|---|------------------------|-----------|
| Pharmacogenomics: Unlocking the Human
Genome for Better Drug Therapy | HL McLeod,
WE Evans | 41:101-21 |
|---|------------------------|-----------|

- | | | |
|--|----------------------|-----------|
| Antisense Oligonucleotides: Promise and
Reality | I Lebedeva, CA Stein | 41:403-19 |
|--|----------------------|-----------|

- | | | |
|------------------------------------|----------------------------------|------------|
| Glycopeptide Antibiotic Resistance | J Pootoolal, J Neu,
GD Wright | 42:381-408 |
|------------------------------------|----------------------------------|------------|

- | | | |
|---|-------------------------|-----------|
| Complementary and Alternative
Therapeutics: Rigorous Research is
Needed to Support Claims | JF Kinsel,
SE Straus | 43:463-84 |
|---|-------------------------|-----------|

- | | | |
|---|--------|-----------|
| Muscarinic Acetylcholine Receptor
Knockout Mice: Novel Phenotypes and
Clinical Implications | J Wess | 44:423-50 |
|---|--------|-----------|

- | | | |
|--------------------------------|---------------------|-----------|
| Pleiotropic Effects of Statins | JK Liao,
U Laufs | 45:89-118 |
|--------------------------------|---------------------|-----------|

- | | | |
|--|---------|-----------|
| The Magic Bullets and Tuberculosis Drug
Targets | Y Zhang | 45:529-64 |
|--|---------|-----------|

- | | | |
|--|-----------------------------|-----------|
| Molecular Mechanisms of Resistance in
Antimalarial Chemotherapy: The Unmet
Challenge | R Arav-Boger,
TA Shapiro | 45:565-85 |
|--|-----------------------------|-----------|

- | | | |
|--|---|-----------|
| Hepatic Fibrosis: Molecular Mechanisms
and Drug Targets | S Lotersztajn,
B Julien,
F Teixeira-Clerc,
P Grenard, A Mallat | 45:605-28 |
|--|---|-----------|

DRUG DEVELOPMENT SCIENCE

- | | | |
|---|-----------------------------|-----------|
| Use of Biomarkers and Surrogate
Endpoints in Drug Development and
Regulatory Decision Making: Criteria,
Validation, Strategies | L Lesko,
AJ Atkinson Jr. | 41:347-66 |
|---|-----------------------------|-----------|

Molecular Basis of Environmentally Induced Birth Defects	RH Finnell, J Gelineau-van Waes, JD Eudy, TH Rosenquist	42:181-208
Protein Tyrosine Phosphatases: Structure and Function, Substrate Specificity, and Inhibitor Development	Z-Y Zhang	42:209-34
Designing Inhibitors of Cyclin-Dependent Kinases	IR Hardcastle, BT Golding, RJ Griffin	42:325-48
Protein Flexibility and Computer-Aided Drug Design	CF Wong, JA McCammon	43:31-45
Gene Therapy with Viral Vectors	NA Kootstra, IM Verma	43:413-39
Biomarkers in Psychotropic Drug Development: Integration of Data across Multiple Domains	PR Bieck, WZ Potter	45:227-46
Systems		
Neurogenesis in the Adult Brain: New Strategies for Central Nervous System Diseases	D Lie, H Song, SA Colamarino, G Ming, F Gage	44:399-421
DEVELOPMENT AND AGING		
Developmental Neuropathology of Environmental Agents	LG Costa, M Aschner, A Vitalone, T Syversen, OP Soldin	44:87-110
Neonicotinoid Insecticide Toxicology: Mechanisms of Selective Action	M Tomizawa, JE Casida	45:247-68
MUSCLE AND ADIPOSE TISSUE		
β -Adrenergic Receptors and Regulation of Energy Expenditure: A Family Affair	J Robidoux, TL Martin, S Collins	44:297-323
Fat Cells: Afferent and Efferent Messages Define New Approaches to Treat Obesity	M Lafontan	45:119-46

IMMUNE SYSTEM/INFLAMMATION

- Signal Transduction by Cell Adhesion
 Receptors and the Cytoskeleton:
 Functions of Integrins, Cadherins,
 Selectins, and
 Immunoglobulin-Superfamily Members RL Juliano 42:283-323
- Structure, Function, and Inhibition of
 Chemokines EJ Fernandez, E Lolis 42:469-99
- Innate Immune Responses to Microbial
 Poisons: Discovery and Function of the
 Toll-Like Receptors B Beutler 43:609-28
- Regulation and Inhibition of Arachidonic
 Acid (omega)-Hydroxylases and
 20-HETE Formation DL Kroetz, F Xu 45:413-38

CENTRAL NERVOUS SYSTEM

- Anesthetics and Ion Channels: Molecular
 Models and Sites of Action T Yamakura,
 E Bertaccini,
 JR Trudell,
 RA Harris 41:23-51
- Interactions Between Monoamines,
 Glutamate, and GABA in
 Schizophrenia: New Evidence A Carlsson, N Waters,
 S Holm-Waters,
 J Tedroff, M Nilsson,
 ML Carlsson 41:237-60
- Drug Treatment Effects on Disease
 Progression P Chan, N Holford 41:625-59
- Molecular Targets of Lithium Action CJ Phiel, PS Klein 41:789-813
- Neurokinin1 Receptor Antagonists as
 Potential Antidepressants SC Stout, MJ Owens,
 CB Nemeroff 41:877-906
- Glutamatergic Mechanisms in
 Schizophrenia G Tsai, JT Coyle 42:165-79
- The Spinal Phospholipase-
 Cyclooxygenase-Prostanoid Cascade in
 Nociceptive Processing CI Svensson,
 TL Yaksh 42:553-83
- Alzheimer's Disease: Molecular
 Understanding Predicts Amyloid-Based
 Therapeutics DJ Selkoe, D Schenk 43:545-84
- Neurogenesis in the Adult Brain: New
 Strategies for Central Nervous System
 Diseases D Lie, H Song,
 SA Colamarino,
 G Ming, F Gage 44:399-421

Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications	J Wess	44:423-50
Analysis of GABAA Receptor Function and Dissection of the Pharmacology of Benzodiazepines and General Anesthetics Through Mouse Genetics	U Rudolph, H Möhler	44:475-98
CRF and CRF Receptors: Role in Stress Responsivity and Other Behaviors	TL Bale, WW Vale	44:525-58
Glyceraldehyde-3-Phosphate Dehydrogenase, Apoptosis, and Neurodegenerative Diseases	D-M Chuang, C Hough, VV Senatorov	45:269-90
Actions of Adenosine at its Receptors in the CNS: Insights from Knockouts and Drugs	BB Fredholm, J-F Chen, SA Masino, J-M Vaugeois	45:385-412
Dual Specificity Protein Phosphatases: Therapeutic Targets for Cancer and Alzheimer's Disease	AP Ducruet, A Vogt, P Wipf, JS Lazo	45:725-50
AUTONOMIC NERVOUS SYSTEM		
Genetic Variations and Polymorphisms of G Protein-Coupled Receptors: Functional and Therapeutic Implications	BK Rana, T Shiina, PA Insel	41:593-624
Biochemical Mechanism of Nitroglycerin Action And Tolerance: Is This Old Mystery Solved?	H-L Fung	44:67-85
CARDIOVASCULAR SYSTEM		
Endothelin System: The Double-Edged Sword in Health and Disease	RM Kedzierski, M Yanagisawa	41:851-76
K ⁺ Channel Structure-Activity Relationships and Mechanisms of Drug-Induced QT Prolongation	CE Clancy, J Kurokawa, M Tateyama, XHT Wehrens, RS Kass	43:441-61
Novel Angiogenic Signaling Pathways and Vascular Targets	R Bicknell, AL Harris	44:219-38

- | | | |
|--|---|-----------|
| Pleiotropic Effects of Statins | JK Liao, U Laufs | 45:89-118 |
| Nitroxyl (HNO): Chemistry, Biochemistry,
and Pharmacology | JM Fukuto,
CH Switzer,
KM Miranda,
DA Wink | 45:335-55 |

- | | | |
|--|--|-----------|
| The Cardiac Fibroblast: Therapeutic Target
in Myocardial Remodeling and Failure | RD Brown,
SK Ambler,
MD Mitchell,
CS Long | 45:657-87 |
|--|--|-----------|

ENDOCRINE SYSTEM

- | | | |
|--|-------------------|-----------|
| Neurotrophic and Neuroprotective Actions
of Estrogens and Their Therapeutic
Implications | SJ Lee, BS McEwen | 41:569-91 |
|--|-------------------|-----------|

PULMONARY SYSTEM

- | | | |
|---|-----------|----------|
| Cytokine Modulators as Novel Therapies
for Asthma | PJ Barnes | 42:81-98 |
| Novel Pharmacological Approaches to
Manage Interstitial Lung Fibrosis in the
Twenty-First Century | SN Giri | 43:73-95 |

Miscellaneous

TECHNIQUES

- | | | |
|---|---------------------|-----------|
| Challenges for Biomedical Informatics and
Pharmacogenomics | RB Altman, TE Klein | 42:113-33 |
|---|---------------------|-----------|

ENVIRONMENTAL TOXICITY

- | | | |
|--|--|------------|
| Challenging Dogma: Thresholds for
Genotoxic Carcinogens? The Case of
Vinyl Acetate | JG Hengstler,
MS Bogdanffy,
HM Bolt, F Oesch | 43:485-520 |
| Neonicotinoid Insecticide Toxicology:
Mechanisms of Selective Action | M Tomizawa,
JE Casida | 45:247-68 |



